Category: ACN Newswire

HONG KONG, Sep 2, 2025 - (ACN Newswire via SeaPRwire.com) - On August 29, Yuzhou Group Holdings Company Limited (01628.HK) announced that its offshore debt management and restructuring efforts, which spanned over three years, have yielded decisive results. The offshore restructuring has officially taken effect, marking a key step in improving the Company’s liquidity and optimizing its financial structure, laying a solid foundation for future robust operations.Optimize Capital Structure, Enhance Financial Stability and Achieve Sustainable DevelopmentAfter multiple rounds of negotiations, the final arrangement encompassed 15 senior notes, one perpetual bond, four secured notes, one syndicated loan, and one bilateral loan. As consideration for the restructuring, Yuzhou Group issued new bonds with an optimized structure, including short-term, medium-term, and long-term bonds. This arrangement significantly reduced financing costs, lowered the Group’s outstanding offshore debt, alleviated financial pressure, optimized its capital structure, and enhanced financial soundness and sustainability.Gain Support from Shareholders and the Market, Consolidate the Interests of all Parties, and Work Together to Move ForwardAs a key component of the plan, certain creditors will receive 5,645 million newly issued shares, representing approximately 37.94% of Yuzhou Group’s issued shares after the restructuring. This further solidified the shared interests of creditors and the Company. In addition, Yuzhou Group raised nearly HK$100 million through a rights issue to cover restructuring-related expenses and replenish working capital. The arrangement not only set a market precedent but also garnered a positive response from minority shareholders, reflecting strong recognition and confidence from shareholders and the market in both the rationale of the plan and the Group’s future development prospects.The core objective of this restructuring plan was to adjust the scale of Yuzhou Group’s offshore debt to a reasonable level, restore the soundness and sustainability of the capital structure, and ensure the continued operation and healthy development of the business. At the same time, the plan aims to ease liquidity pressure, align the new repayment schedule with the operating environment of China’s real estate industry and the Group, and ensure the fair treatment and protection of all stakeholders’ rights, striving to maximize overall value.Respond to Policy Calls, Fulfill Social Responsibilities, and Consolidate Corporate ValueFollowing the completion of the restructuring, Yuzhou Group will continue to respond to policy initiatives, fulfill its commitment to “guaranteeing housing delivery”, strengthen cash flow management, enhance internal revenue generation capabilities, and ensure stable business operations. Structural deleveraging measures are expected to help the Group achieve a long-term sustainable capital structure and reduce overall operational risks. The Company will steadily enhance its operating capacity and remain focused on creating value for all stakeholders.Industry observers note that the completion of the restructuring not only relieves near-term financial pressure but also represents an important step for Yuzhou Group in pursuing long-term stability and growth amid the ongoing adjustment of China’s real estate sector. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月2日 - (亚太商讯 via SeaPRwire.com) - 8月29日，中国新能源汽车行业中的知名企业——赛力斯（601127.SH）发布2025年半年报。数据显示，赛力斯上半年营业收入624.02亿元，归属于上市公司股东的净利润29.41亿元，同比增长81.03%；研发投入51.98亿元，同比增长154.9%。2025年1-6月赛力斯新能源汽车销量达172,108辆，展现出强劲竞争力与综合实力。2025年上半年，赛力斯高端智能电动汽车销量显著增长，有力地推动了公司利润的大幅提升。这一优异成绩的取得，主要得益于问界优异的产品力及高质量的交付能力。具体而言，魔方技术平台做为公司的产品与研发基石，为系列车型的高效开发提供坚实支撑。同时，公司的超级工厂推动新车实现快速垂直上量，速度抢占市场先机，此外，公司的数智质量体系全方位保障批量化产品的卓越质量，为其铸就了行业质量典范，新豪华服务更是持续引爆用户口碑，赢得市场广泛赞誉。未来，赛力斯将继续高举高端智能电动汽车的大旗，坚定锚定高端智能电动汽车这一主航道，持续引领行业发展，为用户提供更加卓越的产品与服务。问界系列持续迭代升级 彰显强大竞争力和品牌魅力2025年上半年，问界系列新品不断推陈出新，持续迭代升级。问界新M5 Ultra、问界M9 2025款、问界M8等车型相继隆重上市，凭借其卓越的性能、创新的科技以及精致的设计，赢得了市场的广泛赞誉和用户的一致青睐，展现了问界品牌的强大竞争力和品牌魅力。得益于全链体系能力的显著提升，问界在中国新能源豪华品牌领域持续刷新交付速度的纪录。截至2025年8月，问界全系累计交付已超75万辆。其中，问界M9累计交付超22万辆，稳居50万级豪华车市场销冠；问界M8上市即热销，累计交付突破7万辆，上市4个月蝉联 40万级销量冠军。此外，根据杰兰路《2025年度上半年新能源汽车品牌健康度研究》显示，问界品牌荣膺2025年上半年品牌发展信心指数第一名，问界M9以85.2分位列新能源车型净推荐值NPS总榜第一名，彰显强大的品牌实力与创新活力。尤为值得一提的是，家庭智慧旗舰SUV问界M8纯电版已于2025年8月25日正式登陆市场，与此同时，全新问界M7也已蓄势待发，计划于9月正式推向市场。随着这一系列新品的陆续推出，问界将进一步优化与完善其产品矩阵，持续巩固其在新能源豪华车市场的领先地位，为用户提供更加卓越的出行体验。持续加大研发投入力度 构筑坚固技术壁垒在持续丰富产品矩阵的同时，赛力斯不断强化技术创新，加大研发投入力度，大力培育新质生产力。数据显示，2025年上半年研发投入51.98亿元，同比增长154.9%；研发人员共计6,984人，同比增长26.6%，占公司总人数的比例提升至36%。在2025年上海车展上，赛力斯隆重发布了智能安全体系，该体系以场景定义安全，全面覆盖「生命保护」「车身防护」「健康呵护」「隐私守护」四大核心安全领域，构建起全方位、多层次的智能安全防护架构，致力于为用户提供全生命周期的安全保障，全面守护用户安全。此前，赛力斯凭借一系列重大技术成果，成功构筑了坚固的技术壁垒。赛力斯魔方技术平台、赛力斯超级增程、赛力斯超级工厂等创新成果相继落地，为公司的技术发展提供了强大支撑。此外，赛力斯还建设了行业内首个「零碳智慧物流港」，树立了汽车制造业低碳物流管理的新标杆，引领了行业绿色发展的新趋势。品牌价值大幅提升 获众多机构强烈看好作为全球第四家实现盈利的新能源车企，今年上半年，赛力斯紧紧围绕产品矩阵优化、技术创新和经营效率提升等核心领域，持续加大投入，精准发力，取得了诸多亮眼的成绩。在2025年《财富》中国500强排名中，赛力斯位列第169位，相较去年上升235个位次，成为排名跃升幅度最大的公司。今年8月发布的《TopBrand 2025中国品牌500强》榜单显示，公司凭借领先的品牌建设成果与市场影响力，以1755.23亿元的品牌价值荣登中国品牌500强，排名第92位，位列汽车行业前十。8月28日，全国工商联发布的「2025中国民营企业500强」榜单显示，赛力斯位列榜单第59位，大幅跃升174位，居重庆民企首位。与此同时，资本市场对赛力斯的发展前景亦给予了积极关注与高度认可，持续看好其后市成长性。据相关统计数据显示，近半年来，已有近40家券商机构给予赛力斯「买入」评级。这一广泛的积极评价，反映了市场对赛力斯未来发展的坚定信心。总体而言，2025年上半年，赛力斯在新能源汽车领域展现出了强劲的发展动力与巨大潜力。展望未来，公司将继续依托其在新能源汽车领域的深厚技术积累、卓越产品竞争力以及强大的市场拓展能力，持续巩固并提升其在行业内的领先地位，致力于为股东和投资者创造可观的回报，为推动新能源汽车行业的发展贡献更多力量。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月2日 - (亚太商讯 via SeaPRwire.com) - 近日，全球仓储机械人第一股——北京极智嘉科技股份有限公司（「极智嘉」，2590.HK）交出一份亮眼的中期成绩单。公司上半年营收订单实现强劲增长，经调整EBITDA转正，成为港股机器人中首家实现转正的公司，进一步巩固了其在全球移动机器人的领先地位及商业化韧性。不久前，公司重磅发布全新通用机械臂操作技术方案及全球首个专为仓储场景打造的具身智能基座模型 Geek+ Brain，以攻克超大规模SKU商品精准拣选与高效适应的行业难题，标志着公司在具身智能从技术架构到应用闭环实现关键突破。这一成果，不仅意味着极智嘉技术版图从移动机械人领域延伸至机械臂智能应用，也为其业务增长开辟全新想象空间。迭加其中期业绩释放的强劲增长信号，极智嘉凭借「技术突破 + 业绩兑现」的双重优势，已成为港股市场「AI+机械人」 赛道中兼具稀缺性与成长性的优质目标。业绩加速兑现 投资价值广受市场认可商业化方面，极智嘉已经走在行业前列。2025年上半年，极智嘉延续强劲增长势头。最新中期业绩数据显示，上半年公司实现收入人民币10.25亿元，同比增长31.0%；经调整净亏损大幅收窄94%。经调整EBITDA首次转正，达到人民币1,162万元，收入与利润改善双向发力，逼近盈利拐点，显示其商业模型已经跑通。同时，公司在大客户复购、新客户、新行业和新管道拓展方面均实现突破性进展。2025年上半年，公司录得订单人民币17.60亿元，同比增长30.1%，其中，最大单笔订单额超亿元。一方面，极智嘉继续赢得大客户认可，包括全球知名跨国消费品、跨境电商、汽车制造、服装行业巨头的复购。截止2025年6月30日，极智嘉服务福布斯世界500强企业超65家，终端客户总数超850家。另一方面，公司持续拓展新客户、新行业和新渠道，报告期内，新增超60家终端客户，并在杂货零售、食品饮料行业取得重大进展，新增渠道商超40家，为业务持续高速增长奠定了坚实基础。与此同时，公司持续深化全球布局，截止2025年6月30日，已向全球40多个国家和地区交付了超66,000台机器人，具备完善的全球业务和服务网络，覆盖超过52个服务站点、12个备件中心以及超过310名工程师。值得注意的是，公司全球化布局下加速释放盈利潜力，2025年上半年，非中国大陆收入占比79.5%，非中国大陆市场的毛利率达46.2%。资本市场亦对其发展前景表示认可。近期，极智嘉获国信证券、德银、中信证券、大摩、招银国际等多家机构发布研报，给予其正面评级，一致看好其未来发展。国信证券研报指出，极智嘉通过AI技术架构+移动机器人(AMR)+机械人解决方案提升用户粘性，盈利持续好转，同时设立具身智能公司提升机械手拣货、通用机械人制造等能力，未来智能化优势、规模效应有望逐步显现。中信证券看好极智嘉AMR机械人基本盘进入高景气发展周期，战略布局具身智能机械人，公司估值有望打开，首次覆盖并给予其「买入」评级。招银国际透过比较同业产品及计算客户投资回报率，进一步确认了极智嘉的竞争优势，并认为极智嘉作为港股市场首个仓储机械人企业具备稀缺性价值。具身智能技术+平台突破 迈向「机械人通用仓储机械人」仓储物流场景凭借其庞大的市场规模、明确的作业流程与迫切的智能化需求，成为具身智能最适合技术落地、商业化价值最高的核心赛道之一。一直以来，「货物多样性、环境动态性」的特性，使得仓库超大规模拣货场景成为最难被机械人完全替代的环节之一。仓储场景下的通用具身智能，将是接下来仓库通用机械人的核心基础。Geek+ Brain平台为极智嘉通用仓储机械人提供「超级大脑」。而首个通用机械臂操作技术方案，通过新一代具身智能技术首次系统性地解决了海量商品形态、材质差异带来的机械臂抓取难题，实现了全品类、全场景、高适应性的自动拣货。该技术具备四大亮点：基于统一协同的多工感知模型、基于仿真增强的完整三维形状预测、多维度感知以及基于强化学习的通用抓取策略，为客户实现Model-free、99.99%+ 准确率、百毫秒级别推理以及本地化模型四大价值。该通用机械臂操作技术方案的发布，突破了传统机械臂受限于 SKU 差异的瓶颈，成功破解仓储超大规模商品拣选难题，让「无人拣选」成为现实，标志着仓储自动化迈入新阶段。机械臂拣选工作流程图通用机械臂货品拣取技术的四大客户价值作为连续6年全球仓储履约机械人市占率第一的公司，极智嘉在仓储领域的深厚场景认知、全球客户资源和业务网络，为公司发展通用仓储机械人带来天然优势。依托强大的产品技术研发和业务拓展能力，极智嘉正率先突破仓储场景下的通用具身智能，推动仓储行业向「 真无人、全智能」时代迈进，打开具身智能的发展空间。从仓储移动机械人到通用仓储机械人，极智嘉正在构建一条清晰的成长曲线：既有业务持续放量，创新技术拓展边界，全球化客户网络与高复购率加速形成正循环。随着在具身智能领域的持续突破，公司有望迎来业绩与估值的双重提升，打开长期配置的新窗口。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月2日 - (亚太商讯 via SeaPRwire.com) - 2025年中期，首程控股营收7.31亿港元，同比增36%；归母净利润3.39亿港元，同比增30%；资产融通板块收入同比飙升69%，"资产运营+资产融通"双轮驱动成效显著。机器人赛道是战略核心，公司已投资宇树科技、银河通用、北京人形机器人创新中心等企业，覆盖人形、工业、医疗机器人领域，通过"资本+场景"赋能技术落地，如新能源汽车产线改造、智慧充电站运营等。在公开的中期业绩路演上，董事会办公室总经理康雨指出："机器人产业已经从技术突破走向场景兑现，但要大规模量产，还必须补齐上游材料短板。"为此，公司同步宣布通过全资子公司设立"首程机器人先进材料产业有限公司"，聚焦电子皮肤、腱绳材料和轻量化PEEK等关键材料。康雨强调，这一布局将与整机和应用形成呼应，真正打通"上游材料—中游整机—下游应用"的全链条。财务方面，公司现金储备超80亿港元，有息负债率仅7.9%，连续三年获AAA主体评级，财务安全垫突出。今年全年计划派息11.59亿港元，股息率近8%，并已累计回购超4000万股，彰显管理层对长期价值的信心。战略上，公司正从传统基建运营商向科技新基建平台转型。停车与REITs业务提供稳定现金流，机器人业务成为增长引擎，下游应用已落地多个场景：如与阿尔特汽车合作推动汽车产线自动化；与万勋科技共建成都ICD自动充电站；北京大学首钢医院已引入术锐手术机器人；在北京"冰丝带"场馆外打造的机器人体验店，日均流水超3万元，并将在国庆期间推出首家"机器人4S店"，推动机器人走向消费端。康雨在路演中还特别提到，首程是宇树科技董事会中唯一的上市公司股东，公司通过北京机器人产业发展基金持有宇树约4%的股份。随着宇树IPO推进，首程的资产将迎来重估，这也将进一步增强资本市场对公司长期成长性的预期。随着材料公司成立、机器人全链条生态逐步完善，以及被投企业的IPO进展，首程控股的生态协同价值正加速释放，企业估值有望迎来新一轮重估。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

上海，2025年9月1日 - (亚太商讯 via SeaPRwire.com) - 8月28日，由弗若斯特沙利文（Frost & Sullivan，简称："沙利文"）主办，头豹协办的2025第十九届沙利文全球增长、科创与领导力峰会暨第四届新投资大会（以下简称"2025沙利文新投资大会"或"大会"）在上海静安香格里拉酒店成功举办。大会集结超200位海内外重磅嘉宾、超100场演讲/圆桌，现场专业观众超4,000人。本届大会以"智启新程-共塑全球增长极"为主题，由中国上市公司协会、中国广告协会、《中国质量监管》作为支持单位，汇聚全球产业界、学术界、投资界的智慧与力量，共同探讨新时代下中国经济的新增长点、新市场、新赛道。大会为期2天，由一场开幕式、八大分论坛及多场主题活动构成，分别围绕AI与数字经济、生命科学新投资、新消费趋势、ESG与新质生产力、上市公司高质量发展、智能制造出海与中企全球化发展等热门议题进行了深入探讨。200+位嘉宾、100+场演讲，共话"智启新程-共塑全球增长极"沙利文富大为：企业可持续转型需完成"七大阶段"系统跃迁沙利文全球董事局主席富大为表示（David Frigstad）先生表示，企业要实现可持续的转型成长，必须先完成"七大阶段"的系统跃迁：从全景式梳理行业九大价值链的"生态体系"出发，建立汇聚客户、竞对与经济数据的"增长生成器"，进而以CEO视角持续发现商业模式、技术与客户场景等多元"增长机遇"；随后对标全球最佳实践，在客户服务、销售支持、研发与AI整合等各环节做到"奥运级"水准；并以沙利文雷达指数为标尺，用执行力与创新能力双重提升未来增长潜力；最终通过开放共享的"行动社群"携手合作伙伴，把外部资源转化为企业收益。沙利文祖亚儒：全球化视角下的增长范式重塑（沙利文全球总裁兼主管合伙人祖亚儒）沙利文全球总裁兼主管合伙人祖亚儒（Aroop Zutshi）表示，当今世界正进入一个由颠覆性技术、产业融合和地缘政治变化共同驱动的全新变革时代。为此，沙利文提出了以自主研发的 "增长渠道引擎（Growth Pipeline Engine）"为核心的"变革性增长之旅"，帮助企业系统性地识别增长机会、对标全球最佳实践，并构建具有韧性的发展战略。祖亚儒强调，未来的赢家将是那些能够在巨变中不仅生存下来，更能果断转型、把握新机遇，并在"智能革命"中实现持续增长的企业家与企业。沙利文王昕：向世界传递中国的增长、科创与领导力沙利文全球合伙人兼大中华区董事长王昕博士表示，沙利文全球合伙人兼大中华区董事长王昕博士表示，沙利文全球峰会已有近30年历史，在中国已连续举办了19年。十九年来，沙利文峰会的主题，始终围绕：增长、科创与领导力，为企业赋值，为行业赋能，为国家社会经济发展贡献力量。他指出，中国经济长期、持续、稳健的增长，是全球最大利好之一。沙利文不仅研究中国经济当下的增长，更着眼于预测未来。本届大会，沙利文再次更新发布《中国未来50年产业发展趋势白皮书（第四期）》，希望能够帮助大家更好地把握市场机遇、应对挑战。据其介绍，进入中国近30年来，沙利文不仅服务于大量科创企业，自身也积极利用科技创新，如提出"AI+HI"理念，即人工智能+人类智能，赋能传统行业转型升级。王昕博士认为，企业的核心竞争力，是企业家的领导力。沙利文始终坚信，中国企业家要：引领科创，服务人民，报效祖国，走向世界。王昕博士最后强调，沙利文将持续助力中国企业提升国际竞争力，吸引全球了解并投资中国。开幕式现场群星璀璨。上海新金融研究院理事长、上海交通大学上海高级金融学院创院理事长屠光绍、国家质量监督检验检疫总局原总工程师、中国质量万里行促进会原会长刘兆彬、中国广告协会会长、国际广告协会全球副主席张国华、中国肝炎防治基金会理事长王宇教授、中国上市公司协会党委委员、副会长孙念瑞、徐州市国盛集团党委书记、董事长王鹏、全国政协委员、世界发明创新联合会中方代表、江苏商会轮值会长、上海港湾集团董事长徐士龙、兴富资本董事长王廷富等重要嘉宾出席活动，致辞或发表演讲。上海交通大学上海高级金融学院创院理事长屠光绍以"深化金融服务实体经济功能与金融体系变革"为题作主旨演讲。他指出，金融服务实体经济是金融体系的根本宗旨，但金融服务实体经济需要与时俱进，因为经济发展中实体经济的内容和形态在不断变动，实体经济发展方式也在变化，特别是进入高质量发展阶段，金融服务实体经济也面临新的使命。屠光绍具体分析了当前金融服务实体经济的三大任务，一是金融在促进传统经济与新型经济融合发展中服务实体经济发展。当前以科技创新、数字化转型以及绿色低碳发展为代表的新质生产力正驱动经济体系深刻变革，科实融合、数实融合、绿实融合及虚实融合正重塑实体经济形态，金融服务需要面对新的资源要素，新的资产形态，新的市场体系、新的产业格局、新的行业业态、新的企业模式等，金融服务需要提升服务能力；二是从金融助力有效供给与扩大需求两侧服务实体经济发展。进入新发展阶段，我国既面临经济与产业结构转型升级又面临扩大内需特别是扩大消费的任务和挑战，金融服务实体经济需从供给和需求两侧协同发力，一方面通过金融服务促进新质生产力发展和资源要素优化配置，服务现代化产业体系建设，另一方面需要通过金融服务推动内需特别是消费需求提升，这也是服务实体经济，否则经济循环不可持续，这既涉及到消费金融体系健全，也与居民家庭财富管理密切相关；三是以金融支持国内经济循环与国际经济循环互动服务实体经济发展。在全球化变局和中国构建国内大循环为主体的国内循环与国际循环互动的新发展格局中，中国继续推进高水平开放，中国经济在全球经济的地位和影响力进一步提升，同时全球贸易结构和方式发生系列变化，特别是企业出海也成趋势，金融需要适应中国经济的国际化新进程，这既是服务实体经济的重要内容，也是提升中国金融体系包括人民币国际竞争力的重大机遇。屠光绍认为，深化金融服务实体经济的功能需要加快金融体系的变革，以持续增强我国金融服务实体经济的深度与广度。金融强国战略以及金融五篇大文章都为金融体系变革提出了指引。他期待金融行业把握机遇，加快业务转型，提升服务能力，为更好服务实体经济发展、促进经济与金融的良性互动与高质量发展贡献新的力量。原国家质量监督检验检疫总局总工程师、中国质量万里行促进会原会长刘兆彬指出，咨询业作为专业化、智慧化程度很高的生产性服务业，在经济增长、技术创新和投资消费中具有重要作用。然而与此同时，我国咨询业仍存在数据不准、研究成果质量参差不齐等问题。对此，他特别提到研究报告"阳光行动"的发起，旨在推动行业更加规范、透明和高质量发展。进一步谈到经济增长背景时，他强调应从全球与中国的经济周期入手，科学研判发展趋势，并提出中国已跨越初级阶段，正迈向中等及更高发展阶段。他认为，未来中国经济增长的核心动力在于"技术创新与制度变革双轮驱动"，并重点展望了新能源革命、智能化与生物技术等领域的机遇。中国广告协会会长、国际广告协会全球副主席张国华在开幕式致辞中指出，沙利文作为中国广告协会的理事单位，在品牌认证、数据引用及广告传播等方面与协会保持良好互动。张国华表示，经过四十多年的改革开放，中国在原材料、设计、制造和营销等领域均取得显著进步，但与此同时，中国品牌仍存在"好产品卖不出好价格"的问题，国际认知度不足。他提到，品牌建设离不开权威第三方的支持，沙利文凭借专业团队与数据积累，能够帮助企业在品牌塑造和上市路演中展现价值。此外，他还强调，在国家设立品牌日、全社会日益重视品牌发展的背景下，企业更需注重提升品牌影响力和议价能力。最后，他预告了即将在北京举行的中国国际广告节及亚洲广告大会，并诚挚邀请企业积极参与，共同推动中国品牌走向世界。中国肝炎防治基金会理事长王宇教授指出，我国经济社会正处于转型发展关键期，企业增长既面临挑战，也蕴含机遇。与此同时，人工智能、芯片与算力、机器人、新材料、新能源等前沿科技加速渗透，带动新产业蓬勃发展。尤其是生物医药领域表现活跃，成为新经济增长点。王宇教授强调，过去一年我国在医药健康领域成果频出，小分子化学药、抗体药物、细胞疗法等不断涌现，研发实力与市场潜力持续增强，并在国际市场上引发广泛关注。他进一步提到，当下国内卫生总费用将突破10万亿，需求快速增长推动健康管理等新趋势兴起。最后，王宇教授寄语，预祝大会圆满成功。中国上市公司协会党委委员、副会长孙念瑞表示，随着新"国九条"等政策落地，A股上市公司发展质量与投资价值持续提升。截至目前，A股上市公司总数达5,400余家，总市值108万亿元，2024年研发投入1.88万亿元，现金分红创历史新高，充分展现出韧性与责任担当。同时，他指出，境内企业加快"出海"，2024年境外收入9.44万亿元，同比增长7.97%，境外上市热潮涌现。他提到，中上协在并购重组、公司治理和投资者保护等多方面持续发力，积极发挥自律管理作用，发挥专业优势、强化合力，加强全国上市公司互学互鉴，积极反映会员诉求，服务、引导上市公司高质量发展。他表示，沙利文是港股IPO行业顾问服务的头部机构，是中上协联系会员的一员，中上协愿与沙利文在内的各方凝聚共识、深化交流，助力产业转型升级，共同推动资本市场高质量发展。徐州市产业发展基金管理有限公司董事长孔雪莉首先介绍了徐州在产业发展上的基础与优势，并指出基金在推动地方经济转型升级中的重要作用。她强调，产业基金不仅是资本的桥梁，更是产业与科技结合的重要纽带，有助于培育新兴产业、加速优质企业成长。与此同时，孔雪莉也谈到，国盛集团始终秉持"专业、合作、共赢"的理念，积极探索多层次资本市场的协同发展路径。她进一步提出，在新一轮科技革命与产业变革背景下，资本需要与产业深度融合，才能实现高质量发展。特别是面对新质生产力与全球化的新趋势，她寄语各方凝聚合力、深化合作，把握创新机遇，共同开创更加广阔的发展空间。全国政协委员、世界发明创新联合会中方代表、江苏商会轮值会长、上海港湾集团董事长徐士龙表示，科技是创新的种子，需要资本的阳光和企业家精神的土壤才能茁壮成长，最终造福民生、推动可持续发展。他呼吁投资界积极为科创项目提供支持，推动新技术从实验室走向应用，为社会创造经济和社会价值。同时，他强调，企业家不仅是创新的主体，更要勇担社会责任，让科技成果惠及最需要的人群，共同守护人类家园，建设更加公平、健康、绿色的未来。兴富资本董事长王廷富表示，2025年是《中国制造2025》十年计划收官实现从追赶到并跑之年，也是特朗普2.0关税战重构全球贸易体系、AI应用元年开启"人类最后一次技术革命"的大变局之年。中国企业应在技术层面从"模仿创新"升级为"引领+改良创新"，在市场层面从"贸易型出海"迈向"产业型出海"，并积极拥抱AI的历史性机遇。面对新形势，增效重于增长，企业需要通过组织与人员优化、极限削减非战略性成本、提升资源使用效率、强化现金预算管理，夯实基础，以稳促进。会上，研究报告"阳光行动"正式启动。国家质量监督检验检疫总局原总工程师、中国质量万里行促进会原会长刘兆彬，国家市场监督管理总局新闻宣传司原二级巡视员丁琳恒，中国质量监管杂志社社长白战林，沙利文大中华区主管合伙人兼总裁王晨晖，范狮营销咨询创始人、《中国质量监管》智库专家杨忠琦共同登台参与仪式启动。据悉，"阳光行动"由《中国质量监管》联合权威媒体、主流研究机构、学术专家及行业资深人士共同发起，旨在有效规范市场研究行为，全面提升行业整体水平与可信度。会上，沙利文全球专家顾问团聘任仪式隆重举行。依托近70年的行业深耕与数据沉淀，沙利文在全球不断吸纳行业内的顶尖专家，并从沙利文中国增长战略、科创、专精特新、生命科学、新质生产力、新消费等多个专家委员会成员中挑选了10余位杰出代表，组建"沙利文全球专家顾问团"，以期为下一个10年的增长范式贡献专业力量。元禾原点管理合伙人费建江、达泰资本创始管理合伙人叶卫刚、常见投资创始合伙人兼总经理王晓瑞、百联挚高资本创始合伙人蔡丹枫在圆桌环节围绕硬科技、消费、医疗等重点投资领域展开探讨，并就IPO放缓、全球产业链重构及科技赛道"内卷"等背景下的投资逻辑进行深入交流，共同分享对2025年资本市场的前瞻性思考。该环节由中新社（北京）国际传播集团有限公司上海分公司总监曹卉担任嘉宾主持。在现场观众的见证下，由沙利文及头豹研究院联合《大国品牌》、中国人民大学新闻传播学院联合推出的"2025年度品牌无形资产增长榜单30强"正式启动。沙利文与香港《凤凰周刊》完成战略签约。沙利文还与微博健康共同启动了#药界风云录#合作项目。近20份白皮书、3大权威榜单集中亮相据悉，本届大会聚焦前沿产业趋势与资本动向，涵盖宏观经济、科技创新、医疗健康、能源储能、人工智能及ESG实践等领域，现场发布包括《中国未来50年产业发展趋势白皮书（第四期）》、《2025年中国PE/VC基金行业CFO白皮书》、《2025年新型功能材料行业发展白皮书》、Growth Opportunities in the Global ESG Climate Risk Platform and Reporting Industry、《建筑运营可持续之路白皮书》、A Path to Sustainable Building Operations、《2025中国ESG最佳企业实践报告》、《2025中国花生油行业白皮书》、《2025中国复合坚果饮品行业发展白皮书》、《2025年中国GenAI行业最佳应用实践》、《2025年AI赋能千行百业洞察》、《2025线粒体医学行业现状与发展趋势白皮书》、《2025中国医疗器械出海现状与趋势蓝皮书》等近20项重磅研究成果，并揭晓"2025中国ESG最佳企业实践榜单"、"2025年中国PE/VC机构CFO榜单"及"2025年中国AI Agent（智能体）最佳实践应用榜单"等一系列评选结果。沙利文增长、科创与领导力最佳实践奖（简称：GIL奖项）旨在表彰各行业中作出突出贡献，取得领导地位的杰出企业。在全球范围内经过近30年的发展，奖项的权威性和公正性受到投资界和金融界，及行业内的广泛认可。截至目前，全球范围已累计表彰5,000+优秀企业。获得沙利文2025GIL全球奖的企业有：江苏中慧元通、云晟研新、沙砾生物、思格新能源、拜尔斯生物、恒医生物、昊海生科、华龛生物等；获得沙利文2025GIL中国奖的企业有：顾家家居、燕之屋、康诺生物、禹王集团、方太、易普集、镁伽科技、复星凯瑞、成功红、凌凯科技、深信科创、瑞玞生物等。获得沙利文2025GIL最佳实践奖的企业有：中关村科金及宁夏交建交通科技研究院。八大主题分论坛 聚焦2025最热产业投融资方向2025沙利文新投资大会不仅打造了产学研投媒紧密融合的创新网络，更为来自各行业的与会嘉宾搭建了充分交流与讨论的专业平台，集中展现了沙利文对全行业及全球资本市场的深刻洞察，提供了大趋势下企业布局未来、创造未来、竞争未来的最佳增长解决方案。ESG与新质生产力论坛在全球产业格局重构、绿色转型加速、技术革命兴起的当下，大会举办的ESG与新质生产力论坛邀请到国轩高科、安永、质子汽车、税友软件等来自全球新能源、人工智能、硬科技领域的重磅嘉宾做客现场，聚焦 ESG 理念与新质生产力的高效融合，通过主题演讲、案例分享和圆桌对话，从政策、产业、技术多维度，探索产业升级与可持续发展路径，助力企业将 ESG 融入核心业务，构建长期竞争力。"智航四海，链启全球"出海分论、中企全球化发展专业服务论坛着国内市场竞争越发激烈，增长空间逐渐趋于饱和，企业急需开辟新的 "战场"。而海外市场，尤其是新兴经济体，拥有庞大且尚未充分挖掘的消费群体。出海不仅能帮助企业突破发展瓶颈，更能让企业在全球舞台上整合资源、提升实力，塑造国际竞争力。8月27日下午，两场聚焦企业"出海"相关的分论坛同时进行，精准切中当下中国企业"走出去"的痛点难点，得到与会者的热烈关注与积极参与。其中，"智航四海，链启全球"出海分论坛邀请到来自日联科技、瑞浦兰钧、凌凯科技、锌盾科技等重磅嘉宾出席分论坛。论坛以中国企业的品牌全球化作为话题引入，深度探讨品牌在中东市场及东盟如何获得新的投资机遇；分享高端装备制造行业的全球化布局，深度解读中国智造企业的全球化竞争力，针对企业走出去的相关法律关切要点做分享。 "中企全球化发展专业服务论坛"则邀请到来自复旦大学国际金融学院，King Road、快仓智能，海翼电商，正见品牌战略，朗言数安，追创创投，沙滩说基金，环世物流集团，钛动，嘉驰国际等重磅企业单位的贵宾出席会议。嘉宾们围绕"品牌出海、科技出海、跨境出海"三大主题以案例分享、圆桌讨论的形式展开讨论。新消费趋势展望论坛8月27日下午，新消费趋势展望论坛邀请到中国轻工业发展研究中心产业技术研究院、禹王集团、广顺兴、椿风茶饮、Twimbit、恒天然、可漾等多个知名消费领域的顶尖专家、行业领军人物、创新企业代表、投资机构及专业服务机构，深度剖析新消费趋势，预见消费者多元化需求的未来图景，挖掘并探讨产业创新发展的新路径与强劲动力。主旨演讲涵盖多个维度：解析中国餐厅创新路径，洞察养生国潮下饮料行业新趋势，探讨情绪与体验消费对商业模式的重塑，并解码消费股香港上市的整体逻辑。AI进化论-物理世界智能体系统构建论坛在人工智能从虚拟迈向物理世界的变革浪潮中，2025年8月28日沙利文新投资大会特别推出由沙利文、头豹联合主办的AI进化论-物理世界智能体系统构建论坛。论坛汇聚全球 AI 行业专家学者、行业领袖、创新企业、投资机构及专业服务机构，邀请到日联科技、易普集、中关村科金、擎朗、深信科创、商汤绝影、松应科技、四维智联、汇智国际等多个知名科技企业的多位重磅嘉宾分享前沿趋势。多场主题演讲亮点纷呈：探讨"人工智能 +"为传统学科注入的新动能，解析2025年最具变革性的50大技术，洞察港股AI行业IPO与再融资态势，分享垂直大模型、具身智能服务机器人、合成数据、智能座舱等前沿热点。生命科学新投资高峰论坛随着全球科技的不断进步和医疗健康需求的日益增长，生命科学领域迎来了前所未有的发展机遇。从基因编辑、精准医疗到生物制药，以及高端医疗器械的研发与应用，生命科学领域的创新成果层出不穷，为全球医疗健康事业注入了新的活力。8月28日，生命科学新投资高峰论坛医药专场邀请到中国肝炎防治基金会、罗氏制药、中国生物制药、百洋医药、思路迪医药、药捷安康、康诺生物、时迈药业、通瑞生物、复星凯瑞、镁伽科技、亦诺微、睿健医药、华毅乐健、西比曼生物科技、中金公司、科律律师事务所、高特佳投资集团等；器械专场邀请到上海创奇健康发展研究院、爱齐科技、上海微创医疗机器人、比邻星创投、唯迈医疗、鱼跃医疗、微创心脉、昊海生物科技、眼得乐、以心医疗、康沣生物、恒医生物、科睿驰、DPM、永新医疗、艾柯医疗、汉诺医疗、北芯生命、摩根士丹利、红杉中国相关单位机构的产业领袖、生命科学企业、投资机构及专业服务机构，聚焦新质生产力的新机遇，深入探讨全球创新发展的新趋势，分享中国生命科学企业国际化的新战略，并共商投资合作的新模式，促进产业界、学术界和投资界的深度合作，共同推动生命科学领域的繁荣发展。上市公司高质量发展分论坛高质量发展是中国式现代化的本质要求，而上市公司作为中国优秀企业群体的代表，则是高质量发展的重要微观基础。8月28日下午将举办上市公司高质量发展分论坛，论坛由沙利文、捷利交易宝、金洲控股、活报告联合主办，集结了东阳光药业、云迹科技、钧达新能源、不同集团、三帝科技、乐摩吧、全联并购公会、金洲控股等践行和推动高质量发展的优秀企业单位代表、行业领袖、投资机构及专业服务机构等多方力量，深入剖析上市公司高质量发展的内涵与路径，探讨全面高质量发展的新动态、新趋势，借助深入的交流和智慧的交融，碰撞出宝贵的创新理念与实操方案，携手描绘上市公司高质量发展的美好蓝图。沙利文全球合伙人兼大中华区董事长王昕博士表示：沙利文的使命是向世界传递中国的增长、科创与领导力，让世界更清晰地看懂中国的价值，也让中国加速拥抱世界的机遇。沙利文峰会在全球有30多年历史，在中国连续成功举办19届，风雨无阻。未来将延续大会立足上海、服务中国、面向全球、合作共赢的承诺，帮助企业实现国内与出海增长战略，通过科创赋能产业转型升级，培育富有领导力的中国企业家，最终促进中国经济社会高质量发展！"1、关于沙利文峰会沙利文创立的增长、科创与领导力峰会在全球超过20个国家和地区，拥有近30年的举办历史，吸引了大量全球1000强公司、国内外顶级金融机构以及其他各类领军企业深度参与，帮助他们在日益复杂多变的世界中，识别机会，不断创新，加速增长，获得领导力的地位。自2008年落地中国至今，已举办至第十九届，沙利文GIL峰会已成为国内优秀企业、投资界、主管机关相互交流成功经验，共同探讨发展方向的重要平台，以及世界了解中国最前沿发展趋势的重要窗口。2025第十九届沙利文全球增长、科创与领导力峰会暨第四届新投资大会汇聚了超4,000位来自各行各业的领先企业，关注产业发展的政府、投资机构、金融机构代表，院校与科研专家,以及知名媒体机构。本次大会的各级合作伙伴包括：大会支持单位：中国广告协会、中国上市公司协会、《中国质量监管》；大会战略合作伙伴：新华社中国名牌、大国品牌、捷利交易宝、金洲控股、凤凰周刊；大会首席媒体合作伙伴：中国新闻社上海分社；大会独家社交媒体合作平台：微博健康；大会高铁媒体支持：路铁传媒；大会战略合作媒体：经济观察报；大会特约合作媒体：中国证券报。大会通过新华社客户端、沙利文视频号、头豹视频号、头豹plus视频号、微博健康、微解药、东财、万得、天风、同花顺、路演中、雪球、价值在线、交易宝、富途、品牌智库研究院等平台线上同步播出。2、关于沙利文全球增长咨询公司，弗若斯特沙利文（Frost & Sullivan，简称"沙利文"）融合全球64年的咨询经验，27年来竭诚服务蓬勃发展的中国市场，以全球化的视野，帮助超10,000家客户加速企业成长步伐，助力客户在行业内取得增长、科创、领先的标杆地位，实现融资及上市等资本运作目标。沙利文深耕全球资本市场及企业咨询服务，通过创新性提出的"全域投资管理 (Total Investment Management, TIM）"为企业提供全方位的投融资及其他各类专业咨询服务，包括投融资CDD、估值服务、技术顾问、财务顾问、ESG、募投可研、债券发行行业顾问、行业顾问、评估服务、奖项服务、行业白皮书、战略及管理咨询、规划咨询、技术洞察等。沙利文大中华区的投融资业务实现了对中国国民经济的全行业覆盖，包括对新经济、新基建等所有经济热点的高度关注，涵盖数字基础设施、消费电子、双碳新能源、医疗与生命科学、餐饮与新零售、半导体与集成电路、智能家居、汽车与出行、康养服务、食品与饮料、信息通信技术、金融科技、地产与物业、矿业冶炼、美容时尚、大数据与人工智能、物流与供应链、建筑科技与装饰装潢、特种新材料、文化娱乐、企业级服务、跨境电商贸易、基础设施建设、环保节能科技、教育与培训等。沙利文团队为企业领袖及其管理团队开展投融资顾问咨询服务以来，已帮助近三千家公司成功在香港及境外上市，是国内投融资战略咨询领域的领军企业。近10年来，沙利文连年蝉联中国企业赴香港及境外上市专业行业顾问市场份额的领导地位；且近年来，沙利文报告也被广泛引用于业内领先的A股、科创板等上市公司的招股文件、一级和二级市场研究报告及其他资本市场公示文件中。64年以来，沙利文通过其遍布全球的近50个办公室，利用强大的数据库和专家库、运用丰富的专业知识和咨询工具，帮助大量客户（包括全球1,000强公司、国内外顶级金融机构以及其他各类领先企业等）完成了包括但不限于尽职调查、估值分析和第三方评估工作等工作，达成了战略目标；创立一系列市场地位研究工具及方法论，创新性提出"FSBV沙利文品牌价值模型"，已向超1,000家企业提供市场地位研究及品牌价值评估服务，持续助力大量中国品牌实现国内与出海增长战略。Media ContactFrost & SullivanShanghai, ChinaContact: Rachel ZhangE: rachel.zhang@frostchina.comT: +86 021-3209-6800W: http://www.frostchina.com/ Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月1日 - (亚太商讯 via SeaPRwire.com) - 8月29日，云顶新耀（01952.HK）公布了截至2025年6月30日的中期业绩报告中报显示。公司实现收入人民币4.46亿元，同比增长48%；运营费用占收入比重大幅减少40.1个百分点，展现了卓越的运营效率。非国际财务准则亏损总额同比收窄31%，剔除非现金项目后毛利率达76.4%。截至6月底，公司现金储备为人民币16亿元，加之8月1日完成配股募资净额15.53亿港元到账，现金余额进一步充实，为商业化扩张与研发投入奠定了坚实的财务基础。基于核心产品的优异表现，公司对实现全年人民币16-18亿元的销售目标充满信心，并力争在2025年下半年实现经营性盈利。交银国际今日发布研报指出，云顶新耀耐赋康的强劲销售表现远超预期，该机构大幅上调公司2026-27年收入预测，并上调目标价至84港元。报告强调，2025年下半年至2026年公司催化剂丰富，包括艾曲莫德在中国获批、商业化和医保谈判，以及自研管线BD合作机会，认为当前估值仍具吸引力，维持"买入"评级。云顶新耀首席执行官罗永庆表示："云顶新耀通过深化’双轮驱动’战略正在突破成为全球领先的Biopharma公司，成功构建以开发高潜力蓝海市场的大单品商业化平台为基石、以自体生成CAR-T平台与mRNA肿瘤治疗性疫苗平台的自主研发与临床转化为引擎的价值体系，推动公司在商业化与研发两大领域实现突破性进展。"核心大单品放量显著，商业化平台释放强劲增长动能在商业化方面，肾病领域大单品耐赋康(R)表现尤为突出。作为全球首个也是目前唯一在中国、美国和欧洲获得完全批准的IgA肾病对因治疗药物，耐赋康(R)在上半年实现收入人民币3.03亿元，同比增长81%。随着扩产申请获批，供应能力显著提升，1-8月累计销售额达到人民币8.25亿元，其中8月单月销售额更高达人民币5.2亿元，显示出强劲的市场需求与放量潜力。公司预计其全年销售额可达人民币12-14亿元，并在2026年保持高速增长，预计实现24-26亿元销售额。另一款核心产品依嘉(R)作为全球首个氟环素类抗菌药物，今年上半年实现收入人民币1.43亿元，同比增长6%。凭借高效的商业化模式，公司聚焦目标核心医院，实现医院端纯销同比增长37%。此外，自身免疫性疾病领域，公司同类最佳药物维适平(R)被视为下一个确定性增长引擎，其在中国大陆的上市申请预计在2026年上半年获批，市场普遍预期其销售峰值可达50亿元。同时，公司位于嘉善的本地化生产项目已于今年3月启动建设，将在未来为维适平(R)的商业化提供强有力的供应保障。全球化管线价值凸显，百亿级潜力产品前景可期在自主研发层面，云顶新耀持续聚焦核心管线突破，并加快全球权益产品的临床开发与国际化布局。新一代共价可逆BTK抑制剂EVER001在今年上半年取得了积极的1b/2a期临床数据。作为强效共价可逆BTK抑制剂，其可用于原发性膜性肾病、IgA肾病、微小病变性肾病等自身免疫性肾病开发，全球患者基数超1000万人，市场空间广阔，预计全球销售峰值超百亿元。在研发进展方面，EVER001预计2026年上半年启动II期Basket Trial（篮式试验），未来有望成为云顶新耀全球化布局的核心品种之一。与此同时，公司依托于业内领先的自研mRNA肿瘤治疗性疫苗平台及自体生成CAR-T平台，构建起具备全球竞争力的研发管线。其中，自体生成CAR-T项目EVM18已完成多项非人灵长类动物（猴）研究，并确定临床候选分子，预计于2025年底前启动临床试验。个性化肿瘤治疗性疫苗EVM16已在中国启动首次人体临床试验并完成患者给药；IIT临床试验已完成低、中剂量组爬坡，初步数据积极。通用型现货肿瘤治疗性疫苗EVM14的新药临床试验（IND）已获美国FDA批准并获NMPA的受理，成为公司首个实现"中美双报"的mRNA肿瘤治疗性疫苗，预计2025年第四季度在中国IND获批。目前，EVM14的美国I期临床试验启动中，预计2025年9月完成首例患者入组。现货型免疫调节疫苗EVM15已完成临床前概念验证，并确定候选分子。战略再布局 提升全球市场竞争力报告期内，公司积极通过资本市场动作增强资金实力与战略灵活性。公司上半年获香港联合交易所批准移除"B"标志，显示出资本市场对云顶新耀的商业化进程及可持续发展能力的认可。除成功完成配售外，公司于8月斥资约3090万美元参与纳斯达克上市公司I-Mab的最新一轮配股。交易完成后，叠加此前已持有的3.2%股份，云顶新耀对I-Mab的持股比例提升至约16.1%，正式成为I-Mab的单一最大股东，加码新一代肿瘤免疫治疗领域的全球布局。分析人士指出，云顶新耀"双轮驱动"战略正在快速兑现：一方面，以耐赋康(R)和维适平(R)为核心的"大单品商业化平台"为公司提供稳定现金流和盈利可见性，同时凭借依嘉(R)、头孢吡肟-他尼硼巴坦、EVER001（希布替尼）及更多引进品种等"高潜组合"，发挥协同效应，预计未来销售峰值超250亿元；另一方面，公司自体生成CAR-T平台与mRNA肿瘤治疗性疫苗平台具备全球商业化与合作潜力，为长期增长注入持续动力。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com.

重点成果- 期内，集团共有2个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因子VIIa N01）。- 2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。- 截至2025年6月30日，集团共有37个肿瘤领域、7个肝病╱代谢领域、13个呼吸系统领域、和6个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中，2个肿瘤领域、1个外科╱镇痛领域产品处在上市申请阶段；11个肿瘤领域、1个肝病╱代谢领域、3个呼吸系统领域、1个外科╱镇痛领域的创新候选药物处于临床III期；另有13个肿瘤领域、6个肝病╱代谢领域、12个呼吸系统领域、6个外科╱镇痛领域的生物类似药或仿制药候选药物处于临床申请及以上开发阶段。- 福可维（盐酸安罗替尼胶囊）是一种新型小分子多靶点酪氨酸激酶抑制剂，目前已获批9个适应症，另有3个适应症处于上市申请阶段。此外，安罗替尼还有多项新适应症处于III期临床研究阶段，包括一线非鳞状非小细胞肺癌、一线胰腺癌等，预计将在未来两年逐步递交上市申请。- 2023-2024年，集团共有5款肿瘤领域的国家1类创新药获批上市，分别为：亿立舒（艾贝格司亭α注射液）、安得卫（贝莫苏拜单抗注射液）、安柏尼（富马酸安奈克替尼胶囊）、安洛晴（枸橼酸依奉阿克胶囊）和安方宁（格索雷塞片）；以及4款肿瘤领域的生物类似药获批上市，分别为：安倍斯（贝伐珠单抗注射液）、得利妥（利妥昔单抗注射液）、赛妥（注射用曲妥珠单抗）和帕乐坦（帕妥珠单抗注射液）。该等产品在2025年上半年快速放量，成为集团收入增长的重要贡献品种。- 拉尼兰诺（泛PPAR激动剂）是一种口服小分子药物，用于治疗代谢功能障碍相关脂肪性肝炎（MASH），目前正在全球开展III期临床试验，已完成全部受试者入组。2023年7月，拉尼兰诺被药品评审中心「CDE」纳入突破性治疗药物程序。拉尼兰诺是中国第一个进入临床III期的MASH口服药物，有望填补中国市场空白。- 天晴速畅（吸入用布地奈德混悬液）是中国首款获批上市的布地奈德雾化剂型仿制药，打破了国内市场长期被原研垄断的局面，为国内气道慢性炎症患者带来了兼具有效性、安全性与经济性的高端制剂产品。该产品已被纳入集采范围，集团及时采取了一系列主动管理措施，包括管道下沉、拓展市场覆盖和集采外市场的二次开发。- 泽普思╱得百安（氟比洛芬凝胶贴膏）是中国首个获批上市的国产凝胶贴膏，连续多年蝉联外用镇痛市场份额第一位。集团聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求，推动泽普思/得百安销售额持续快速增长。集团开发的第二代氟比洛芬贴剂预计将在一年内获批上市。通过剂型升级，二代产品可显著提高药物透皮吸收度，增强贴膏粘附性，从而提升患者的依从性。香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 中国领先的创新研发驱动型医药集团-中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2025年6月30日止6个月（「期内」）之未经审核财务业绩。回顾期内，集团收入同比增长10.7%至约175.7亿元（人民币，下同）。来自持续经营业务之归属于母公司持有者应占盈利财务报表所示约33.9亿元，同比增长约140.2%，基于归属于母公司持有者应占盈利计算之每股盈利约18.82分。归属于母公司持有者盈利同比显著增长主要受惠于本期间收入明显增长及股息收益和投资公允价值变动收益明显增长。归属于母公司持有者之基本溢利（非香港财务报告准则指标）约30.9亿元，同比增长约101.1%。集团流动资金保持充裕，期内有计入流动资产之现金及银行结余约111亿元、计入非流动资产之银行存款约101亿元，理财管理产品总额约92.9亿元，资金储备合共约304.9亿元。董事会建议派发中期股息每股5港仙（2024上半年：3港仙）。销售：研发创新动能强劲，多领域销售成果持续放量集团一直以来重视研发，持续加大投入以提升研发质效，研发实力显著增强，驱动销售收入持续增长，成果丰硕。期内，抗肿瘤用药之收入同比增加24.9%，达约66.9亿元，占集团收入约38.1%。外科／镇痛用药之收入同比增加20.2%，达约31.1亿元，占集团收入约17.7%。肿瘤领域，集团全面布局非小细胞肺癌领域，覆盖多种分型的全线治疗，EGFR/cMet双抗TQB2922即将启动二线非小细胞肺癌III期临床，EGFR/cMet双抗ADC TQB6411 I期临床正在入组，两款产品进度均位于中国前列；深度布局乳腺癌三大亚型， CDK2/4/6抑制剂库莫西利胶囊有望成为HR+/HER2-乳腺癌的BIC疗法，HER2双抗ADC TQB2102较DS-8201潜在安全性优效，多个适应症正在同步拓展，其中三项乳腺癌III期快速推进；系统布局消化道领域结直肠癌、胃癌、胰腺癌、肝癌等核心癌肿，LM-108(CCR8单抗)、TQB2868(PD-1/TGF-β双功能融合蛋白)研发进度全球最快，且目前临床数据展示出了极大潜力。于外科╱镇痛领域，集团持续聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求。期内，集团推动泽普思销售额持续快速增长，而开发的第二代氟比洛芬贴剂预计将在一年内获批上市。同时，2025年5月获批的普坦宁凭借长效镇痛、安全性优异等优势，有望成为该领域新的增长动力。研发：全力以赴推动创新产品开发，加大研发的资金投入于报告期内，集团共有2个创新产品获NMPA批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因数VIIa N01）。2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。一直以来，集团十分重视研发，不断提升研发水平和速度，并视其为可持续发展的基础，加大研发的资金投入。截至二零二五年六月三十日止六个月，研究与开发成本约人民币318,756万元，占本集团收入约18.1%，连同已资本化的研发总开支出在内，约95.7%已计入损益表中。展望：深化创新与国际化布局，加速构建全球医药创新竞争力当前，中国医药产业正迎来历史性发展机遇。在国家创新驱动发展战略的指引下，我国生物医药创新能力显著提升，创新药研发已从「跟跑」逐步迈向「并跑」甚至「领跑」阶段。中国创新药不仅在本土市场构建起强劲的增长势能，更在全球市场逐步崭露头角，日益获得广泛认可，已成为全球医药创新产业中不可替代的重要力量。作为行业领军企业，集团深耕肿瘤、肝病╱代谢、呼吸系统及外科╱镇痛四大核心治疗领域，专注创新，服务病患，目标成为全球领先的制药企业。集团深耕中国市场，同时将战略视野投向全球市场，以国际化加速创新发展。同时，集团大力推进全球战略合作布局，通过商务拓展（BD）、战略收购等多元合作路径，快速充实创新管线储备，强化核心技术平台。2025年7月，集团宣布全资收购礼新医药。礼新医药拥有全球领先的抗体发现和ADC技术平台，包括肿瘤微环境特异性抗体开发平台 (LM-TME™)、针对难成药靶点的抗体开发平台（LM-Abs™），新一代抗体偶联药物平台（LM-ADC™）、以及免疫细胞衔接器平台（LM-TCE™）。此次收购将进一步增强集团的创新研发能力，加速集团的创新业务增长。此外，礼新医药卓越高效的研发团队将加入集团，进一步强化集团的创新研发人才储备，为持续产出高水平创新成果提供保障，助力创新生态的长远发展。未来，本集团将继续聚焦创新，提升四大治疗领域的研发效率与质量，加快国际化步伐，力争实现业务快速发展与业绩稳步提升。有关中国生物制药有限公司（股票编号：1177）中国生物制药，连同其附属公司，是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智慧化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病/代谢、呼吸系统、外科/镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市，2013年入选MSCI全球标准指数之中国指数成分股；2018年入选恒生指数成分股；2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续七年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」，连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料，请浏览: www.sinobiopharm.com Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 由周大福控股战略入股的uSMART盈立证券欣然宣布香港落马洲港铁站，西九龙高铁站分行已正式投入服务，涵盖陆路出入境和高铁枢纽客戶群。为庆祝这一里程碑，盈立证券今日在西九龙分行举行简单而隆重的开幕仪式，并邀得不少财经界精英出席，令活动生色不少。开幕礼上，盈立证券执行董事李建翰先生（Neo Lee）表示：「为提供更便捷的金融服务方便区内居民，盈立集团计划年内于香港及新加坡两地社区内开设分行，连同总部客户专区，服务点增至12个，进驻尖沙咀，铜锣湾，荃湾，上水及上环等核心地区，全面强化区域服务网络，拉近与本地客户的距离，提供更贴心的服务。」「作为港资科技券商No.1^，全球超过800,000用户，盈立证券十分重视提升用户的投资体验，本次开立分行不但提供综合服务，包括投资咨询，办理开户等，还协助长者及初学者处理开户流程，学习App使用方法等，借此深化本地市场，满足客户对相关服务的殷切需求。」Neo Lee续说。(左起︰盈立证券业务拓展总监邓永麟先生、盈立证券香港市场部总监黄晓霖小姐、盈立证券执行董事兼机构业务负责人李建翰先生、盈立证券资产管理兼投研部总监蒋雄先生及盈立证券业务拓展经理林向尊先生)新开张时间内，前往分行打卡即可获赠神秘礼品1份，同时亦可免费享用饮料及手机充电服务，于分行开户更可额外获得丰富礼品。为进一步开拓香港市场，盈立证券推出「Trader账户」，香港本地客户专享美港股一世免佣，美股期权0佣优惠。为感谢客户的支持，uSMART盈立证券亦同时提供多项真全免优惠，不论新客户或现有客户，均可享受，绝无取巧，优惠包括：1)IPO融资认购0息│现金认购0手续费；2)>100只港股ETF 0佣0平台费（当中包括近期投资者热爱的高息股ETF，虛擬資產相關ETF及指数ETF等）；3)月供美港股0佣0平台费0存管费及免代收股息税以上优惠旨在满足短线，中线及长线投资策略，让持有uSMART盈立证券账户的客户均能受惠。Neo Lee在开幕礼上透露，集团正积极增聘人手，扩充香港及新加坡团队，以支持及推进业务发展，提高本地市场竞争力；而集团旗下的美国办公室亦正式进驻至世界金融中心-纽约曼哈顿城中心，并将专注于对接对冲基金，家族办公室及拟赴美上市企业，提供机构经纪、资产配置及投行咨询等专业服务，巩固全球金融科技券商领域的领先地位。展望未来，uSMART盈立证券秉持以客为本的理念，为更多本地投资者提供星级投资体验及优质线下服务，同时亦致力推动金融服务的创新与升级，为全球客户创造更多价值。^"港资科技券商No.1"是取自捷利金融云截至2025年5月为止连续超过一年数据，uSMART盈立证券为香港本地港资互联网券商月成交总额排行第1。优惠受条件及细则约束关于uSMART盈立证券：由周大福控股战略入股的盈立证券是一间领先科技港资券商，成立于2018年，7年来凭借卓越的战略规划和创新能力，致力于将科技与金融深度融合，业务范围涵盖证券，资产管理，财富管理等领域，为全球投资者独家研发了金融证券交易平台uSMART HK APP和uSMART SG APP，分别由盈立证券（香港）和盈立证券（新加坡）提供服务。集团APP支持港股，美股，A股（沪深港通），新加坡股票，日本股票，英国股票，美股期权，ETF，基金，债券，资管，结构化票据，期货，加密货币，贵金属，黄金和外汇等多元化的投资交易服务，此外更为超高净值个人与家族，企业提供度身订制服务，打造全方位综合性资产管理解决方案。详情可浏览 https://hk.usmartglobal.com/传媒查询：黄晓霖Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 8月18日，康哲药业发布2025年中期业绩，公司营收和利润同比均实现增长，战略转型成效初显。报告期内，公司实现营业收入约40.0亿元（人民币，下同），同比增长10.8%。若全按药品销售收入计算则营收约46.7亿元，同比增长8.9%。实现净利润约9.3亿元，同比增长3.1%。具体来看，康哲药业已走出国采阴霾，业绩将回归持续上升轨道。公司主要非国采独家/品牌产品及创新产品全按药品销售收入合计约29.0亿元，同比增长20.6%，占总收入比重升至62.1%。公司独家/品牌产品、创新产品竞争格局良好、增长可预期性强，目前已成为拉动业绩向上的主力军。根据业绩公告，公司自2018年起擘画"新康哲"转型蓝图，以"产品创新、商业革新、国际拓展"三大战略为支柱，构建可持续的第二增长曲线。行至2025年上半年，良好的经营业绩及创新成果持续落地，证实战略升级已逐步兑现为硬核战果。"新产品"战略推动创新价值兑现 夯实增长后劲立于公司三大战略之首的"产品创新"战略，依托"海外授权+国内合作+自主研发"三维创新机制，持续注入高价值短、中、长期管线，成为驱动增长的重要引擎。目前，创新战略已进入持续收获期，新产品正不断释放商业与临床价值。截至目前，公司已有5款创新药成功于中国实现商业化；2025年内，芦可替尼乳膏和德昔度司他片两款创新产品亦有望获批上市。芦可替尼乳膏是美国FDA以及欧洲EMA批准的首个、也是唯一一个局部JAK抑制剂非节段型白癜风复色产品，有望成为中国获批上市的首款白癜风治疗药物，将填补市场空白，为中国白癜风患者带来新希望。此外，阿尔茨海默病新药ZUNVEYL的中国上市申请(NDA)亦已于今年7月获受理；消费医疗产品注射用聚左旋乳酸微球填充剂已获得上市批准，进一步丰富公司多元化产品矩阵。在研创新管线中，已有多款重磅候选药物进入中国后期临床开发阶段，预计将在未来1-3年内陆续进入商业化，形成持续放量的新动力。其中，合作产品注射用Y-3已完成中国III期临床，该产品为原创单分子1类新药，亦为全球唯一进入临床研究的非肽类PSD95/nNOS解偶联剂，并有望成为首个治疗缺血性卒中并预防卒中后抑郁焦虑的双功能脑细胞保护药物。另一个口服小分子1类新药ABP-671（URAT1抑制剂）用于治疗痛风及高尿酸血症，目前其中国IIb/III期临床正有序推进中。相较现有主流药物，该产品有潜力以更低剂量将尿酸降低至更低水平，并具有溶解痛风石的能力，有望为患者提供疗效更优、安全性更高的治疗选择。康哲药业亦持续增厚创新储备，不断夯实全链条创新实力，以实现创新产品分阶段、源源不断获批上市。2025上半年，公司新增ZUNVEYL、MG-K10（长效抗IL-4Rα人源化单抗注射液）两款合作开发创新产品。截至目前，公司累计布局约40款差异化创新管线，其中约20项为自主研发项目。同步推进"新模式"、"新地域"战略 拓展多维增量空间根据业绩公告，康哲药业持续推进"新模式-商业革新"战略，以多元生态锻造抗周期韧性；并坚定执行"新地域-国际拓展"战略，以产业国际化出海模式构建多维增长格局。在商业革新战略下，公司持续聚焦专科领域，同时拓展新零售、新媒体渠道，构建"院内+院外"、"线上+线下"全覆盖的营销推广体系，并持续强化消费医疗产品布局。公司皮肤健康业务"德镁医药"已在这一具消费属性的赛道崭露头角，自2021年独立运营以来，已实现皮肤疾病领域适应症覆盖广度、皮肤处方药收入规模的双重领先，将通过介绍上市、实物分派方式，拟分拆于香港联交所主板独立上市，进一步释放其独立价值与高成长潜力。国际化方面，2025年7月15日，公司以介绍方式成功于新加坡交易所完成第二上市，"产业国际化"战略迈入新里程。以新加坡为枢纽，公司构建起覆盖"研-产-销"的新兴市场全链条业务体系。截至目前，商业化平台公司Rxilient已在东南亚、中东、港澳台等地区累计提交近20款药品和器械注册申请，涵盖皮肤科、眼科、肿瘤、自免、中枢神经等领域。芦可替尼乳膏（白癜风适应症）已在澳门、香港获批，并已递交新加坡、台湾注册申请；静脉注射用特瑞普利单抗（首个被中国NMPA及美国FDA批准上市的国产抗PD-1单抗药物）已提交马来西亚等五国注册申请；替瑞奇珠单抗注射液、蔗糖羟基氧化铁咀嚼片亦在香港获批。同时，公司持股45.0%的联营CDMO生产工厂PharmaGend，目前已具备片剂、胶囊等口服固体制剂年产10亿片的能力，并获得新加坡HSA颁发的生产许可证、美国FDA cGMP认证及瑞士QP审计通过。PharmaGend鼻喷剂、乳膏、注射剂等新产线的建设正稳步推进中，为国际市场提供高标准生产交付能力。展望未来，"新康哲"增长逻辑有望加速兑现，盈利能力与业绩韧性将同步提升。公司正构建以差异化创新为核心、多元生态协同驱动、国际化布局支撑的增长体系，为高质量发展打开长期空间，为全球患者提供高品质医药产品和服务，为股东带来可持续回报。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，其中皮肤健康业务已成为该细分领域的龙头企业，带来专科规模效率。同时，康哲药业持续深化东南亚及中东区域业务发展，助力高质量持续健康发展。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Global leading storage battery company in data center and telecom industries – Shuangdeng Group Co., Ltd. (stock code: 06960.HK), proposes to list its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Shuangdeng Group plans to offer 58,557,000 H Shares (subject to the Over-allotment Option), of which 52,701,000 H Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial offer shares; the remaining 5,856,000 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$14.51 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Shuangdeng Group will open for Hong Kong Public Offering in Hong Kong at 9 a.m., August 18, 2025 (Monday), and close at 12:00 noon, August 21, 2025 (Thursday). Dealings in H shares of Shuangdeng Group on the Main Board of the Hong Kong Stock Exchange is expected to commence on August 26, 2025 (Tuesday). The H shares will be traded in board lot of 500 H shares each. The Company’s stock code will be 06960.HK.China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and CCB International Capital Limited are Joint Sponsors, Sponsor-Overall Coordinators, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Mangers. Sanshui Venture Capital Co., Limited is the cornerstone investor, subscribing for H shares worthing approximately RMB220 million in total.Global leading storage battery company in data center and telecom industriesFounded in 2011 in Taizhou, Jiangsu Province in China, Shuangdeng Group is a leading company in energy storage business for big-data and telecommunication industries. With a deep understanding of the industry and customer demand, Shuangdeng Group has developed industry-leading technologies and multi-pathway products with optimal balance among safety, cost efficiency and performance, which enables it to capture huge growth potential in its industry. According to Frost & Sullivan, in 2024, the Company ranked the first among global telecom base station and data center energy storage battery providers in terms of shipment volume, achieving a market share of 11.1%.With its unwavering commitment to enhance the market recognition of its brand, Shuangdeng Group boast a high-quality global customer base with nearly 30 of the world’s top 100 telecom operators and equipment manufacturers, forging strong relationship with leading telecom operators and telecommunication equipment manufacturers in China, such as China Mobile, China Telecom, China Unicom, and China Tower, as well as prominent international telecommunication giants like Ericsson, Vodafone, Orange, and Telenor. In addition, as of December 31, 2024, Shuangdeng Group served 80% of top 10 Chinese self-owned data center companies and 90% of top 10 Chinese third-party data center companies.R&D capabilities in high safety, cost efficiency and superior performanceShuangdeng Group’s products span diverse application scenarios, including energy storage for telecom base stations, data centers, and the electrical energy storage settings. Shuangdeng Group continuously expand its technology portfolio to encompass lithium-ion batteries, lead-acid batteries, sodium-ion batteries, and solid-state batteries, ensuring it can provide the most suitable products for various application scenarios and diverse customer use. Its R&D efforts are focused on addressing the needs and pain points of customers operating telecom base stations and data centers, with a steadfast commitment to ongoing improvements in safety, cost, and performance of products.Shuangdeng Group has established a technical expert committee led by multiple academicians and comprised of over 30 renowned industry experts. This committee collaborates with distinguished experts from leading institutions such as China Electric Power Research Institute, Tsinghua University, Nanjing University, and Huazhong University of Science and Technology. Together, the Company has developed a long-term, stable research and communication mechanism, regularly engaging in academic exchanges to stay abreast of cutting-edge technological advancements. Through active collaboration between industry, academia, and research, Shuangdeng Group continuously optimizes its product manufacturing process and technologies, driving ongoing innovation. As of August 8, 2025, the Company held a total of 353 patents, including 111 invention patents.Data center business accelerates, emerging as a key growth driverWith the penetration and promotion of big data, technologies, energy storage batteries for data centers have become essential products for ensuring data security and energy security. In 2018, Shuangdeng Group keenly identified the market demands of the internet era and began establishing cooperation relationship with large tech companies and data center operators. Since 2018, the Company has successively collaborated with Alibaba, JD.com, Baidu, GDS, and ChinData. In 2022, Shuangdeng Group innovatively developed the first large-scale dual-function energy storage plan incorporating “backup power + power storage and management” for data centers in China, and supplied our products to the Xiong’an Urban Supercomputing Center, contributing its successful achievement of being recognized as national green data center. Up to August 8, 2025, its energy storage products have been used in hundreds of data centers.According to Frost & Sullivan, in 2024, Shuangdeng Group ranked first among Chinese companies in terms of shipment volumes in the global data center energy storage market and its market share in the global data center market reached 16.1%. Revenues from sales of batteries used in data centers increased by 120% YoY from RMB397.0 million in the five months ended May 31, 2024 to RMB872.9 million in the five months ended May 31. This expansion boosted its contribution to total revenue from 28.4% to 46.7%, making it the company’s largest revenue source. Driven by the increase in revenues from sales of batteries used in data centers, the Company’s total revenues increased from RMB1,394.2 million in the five months ended May 31, 2024 to RMB1,866.6 million in the five months ended May 31, 2025.An experienced and visionary management teamShuangdeng Group is led by a visionary, stable, and highly experienced management team. The Company’s Chairman, Dr. Yang Rui, brings extensive experience in the energy storage battery industry and a global perspective. He has been honored with multiple accolades, including the 2024 Person of the Year in Energy Storage Battery Industry, and Jiangsu Province Excellent Entrepreneur. His forward-thinking strategic decisions have driven the Company’s continuous innovation and growth. Its executive Director and deputy general manager, Dr. Yang Baofeng, is a senior engineer who has received distinguished honors, such as ‘‘Jiangsu Province Technology Entrepreneur’’ and ‘‘Innovation and Entrepreneurship Star.’’ He also serves as Vice Chairman of the China Battery Industry Association and the China Chemical and Physical Power Industry Association. Its senior management team possesses deep expertise in energy storage battery technology and business management. All senior team members have been with us for many years, ensuring effective management collaboration and a unified long-term business strategy.Dr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officer of Shuangdeng Group said, “As a global leading storage battery company in data center and telecom industries, we always adhere to our customer-centric approach and devote ourselves to delivering the most suitable and premium batteries to our customers across various industries, including telecom operators and tech companies. As artificial intelligence technology ushers in a new era of widespread adoption, the surging demand for computing power will drive unprecedented growth in energy needs. In response to the expanding demand for computing power and the increasing energy consumption of data centers, we will maintain our innovative drive to seize growth opportunities in the data center sector and cultivate our second growth pillar. Meanwhile, we will continue to deepen our presence and penetration in existing markets while expanding our global presence, further strengthening our position as a globally leading brand.”Use of ProceedsShuangdeng Group estimates that it will receive net proceeds from the Global Offering of approximately HK$756.3 million, assuming the Over-Allotment Option is not exercised, after deducting the underwriting fees and commissions (assuming the full payment of the discretionary incentive fee) and estimated expenses payable by the Company. Approximately 40.0%, or approximately HK$302.6 million, will be used for the construction of a lithium-ion batteries production facility in Southeast Asia. Approximately 35.0% or approximately HK$264.7 million, is intended to be used to fund the establishment of a research and development center. Approximately 15.0%, or HK$113.4 million, is intended to be used to strengthen its overseas sales and marketing so that the Company can enhance its global presence, better serve its overseas customers and boost its international sales. And approximately 10%, or HK$75.6 million, will be used to provide funding for working capital and other general corporate purposes.For further information, please contact:Porda Havas International Finance Communications GroupMs. Kelly Fung+852 3150 6763kelly.fung@h-advisors.globalMs. May Yang+86 21 3397 8725may.yang@h-advisors.global Copyright 2025 ACN Newswire via SeaPRwire.com.

- The Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today, bringing together approximately 1,890 exhibitors and welcoming over 500,000 visits.- The per capital spending across the five fairs reached HK$1,630.- 48% of respondents believe that health, green and organic food trends are worth paying attention to. Halal food and beverage label at the expo helps promote the development of halal foods.- The five theme days, along with a series of exciting activities effectively boosted local consumption and created a bustling atmosphere.- The International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM) featured 21 prominent speakers who shared innovative achievements and development trends in the globalisation of Chinese medicine.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today. Food Expo PRO and the Hong Kong International Tea Fair, which opened to both industry professionals and the public for the first time, wrapped up successfully on 16 August. The five exhibitions featured some 1,890 exhibitors and attracted over 500,000 visits. The bustling atmosphere resulted in a per capita spending of HK$1,630, once again demonstrating the appeal of this annual event and the public’s purchasing power. Over at Food Expo PRO and the Hong Kong International Tea Fair, there were some 18,500 buyers from 64 countries and regions. Apart from Hong Kong, buyers came from Mainland China, Japan, Korea, Taiwan, as well as ASEAN countries, including Cambodia, Malaysia, the Philippines, Thailand, and Vietnam, among others, highlighting Hong Kong's significant role as a key food trade hub globally. Additionally, the International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, also concluded successfully on 15 August.Sophia Chong, HKTDC Deputy Executive Director, stated: "This year, the event featured five major themes across several exhibitions, complemented by a variety of exciting activities that encouraged people to spend locally. The atmosphere was vibrant, fully reflecting the public's enthusiasm for gourmet food and trendy products. Due to weather conditions on the first day, the opening hours of the public fairs from Friday to Sunday were extended to provide exhibitors with greater opportunities to maximise sales and enhance visitor experiences. The Hong Kong International Tea Fair, which opened to the public over all three days for the first time, attracted significant attention and praise.”Despite challenges from sluggish trade in traditional markets and geopolitical challenges, the HKTDC has consistently focused on driving innovation, helping small and medium-sized enterprises seize global development trends, and creating opportunities through innovative and flexible thinking.Ms Chong added: “At this year's Food Expo and Food Expo PRO, we specifically curated products and services related to halal food, the silver economy, and food technology to meet emerging market demands and capture more business opportunities for exhibitors. We are pleased to see that the five exhibitions successfully generated more business for exhibitors, and the public enjoyed the culinary and shopping experience fully."Per capita spending reached HK$1,630; increased interest in halal foodsDuring the exhibition, the organisers conducted a random sampling survey, interviewing some 1,440 visitors. The per capita spending reached HK$1,630. Over 58% of respondents reported spending HK$1,000 or more at the exhibition, and over 30% indicated that their actual spending exceeded their original budget, demonstrating a strong and thriving consumption atmosphere during the event. The survey results also showed respondents believe that health, green and organic food (48%), and nutritional supplements (36%) trends are worth paying attention to. Among the respondents who are aware that the exhibition has a halal food and beverage label, more than half of the respondents (52%) believe it helps promote the development of halal foods.Vibrant consumption at the exhibition: encouraging sales performanceAs a highly anticipated annual event in the city, the Food Expo is dedicated to highlighting exquisite delicacies and fine wines from around the world. Director of exhibitor Yick Cheong Ho (HK) Limited, Joan Chui, stated that the Flavours of Intangible Cultural Heritage theme day has drawn extra interest and expected revenue of approximately HK$900,000. Some exhibitors are further expanding their business through the Food Expo. Huaying Lei, the chairman of Mayang Blue Phoenix Agricultural Development Co., Ltd from Mainland China stated that the company had signed a RMB60 million contract with a Hong Kong client for agri-products including high-quality edible eggs. Lei believed the Food Expo offers a perfect platform to showcase their wide-ranging products from Hunan Province.The concurrently held Beauty & Wellness Expo offered visitors a diverse range of premium products, with brand Mars, a Taiwan whey protein brand, the brand marketing manager Roy Wong said, “This year, the visitor traffic exceeded our expectations and we expect our on-site sales will increase by 30% to HK$200,000.”The Home Delights Expo showcased a variety of trendy household items and furniture. Andy Tsang, the design director of Renovation Guide Consultant Limited - specialising in interior design and decoration and participating in the expo for the first time - said, “Such a large number of new customers visiting our booth went above and beyond our expectations. We provided quotations to over 20 new clients, and we estimate that sales turnover will be around HK$2-3 million."Trade exhibitions expand business networks; thriving opportunities in halal foodThe 3rd Food Expo PRO and the 35th Food Expo introduced halal food and beverage label last year to help exhibitors expand their market for halal products. This year, more than 120 food suppliers showcased halal products from around the world, a 20% increase compared to last year. Daniel Chan, Director of Hong Kong exhibitor, Koon Chun Hing Kee Soy & Sauce Factory Ltd., said the company had seen many buyers from different countries and regions and discussed cooperations with five Mainland China and local distributors and restaurants and also met a buyer from Indonesia through the Click2Match platform.The new "Coffee" zone also debuted this year, showcasing coffee products, accessories, and machines from various origins. Jin Lu, Operations Director of CSFA Holdings Shanghai Co. Ltd., stated that the company has engaged with nine exhibitors from Mainland China, the U.S., South Korea, and other regions. The company is interested in placing a coffee beans order of approximately 50 metric tons (worth around RMB3 million) from a Yunnan-based supplier, as well as a RMB700,000 order for premium hairtail fish from a Korea exhibitor.The highlight zone, "Food Science and Technology," brought alternative and future food to the attention of professional buyers. My Care Healthcare Limited, a manufacturer of modified soft diet products for the elderly. Founder Francis Ho said they had discussions with nearly 120 buyers on the first day. On the last day of the fair, HKTDC arranged specialised medical industry buyer tours of which there were two potential buyers and the company is in talks with two hospitals to discuss the potential of supplying soft meals to them.The Okinawa Prefectural Government Hong Kong Representative Office organised four Okinawan companies to participate in the Food Expo PRO and successfully connected with buyers from Hong Kong, Mainland China, and international markets. Director Yasutoshi Nohara stated the fair helps them generate around HK$4 million in orders every year. Mr Nohara said the expo has been instrumental in providing them with a great opportunity, particularly to introduce Okinawan products in the Greater Bay Area and expand beyond Hong Kong with items that have not been shown in other markets before, such as soft shell turtle and Motobu beef.Sichuan Sentaiyuan Biotechnology Co., Ltd. has participated in the Food Expo PRO for four consecutive years, promoting healthy products. The company’s CEO, Liu Lei shared, “On the first day of the Expo, we met a long-time Hong Kong client in person for the first time, leading to a successful deal worth over US$5 million. The HKTDC also introduced several potential buyers from Japan, Singapore, and other regions and we expect deals to be finalised soon.” Mr Lei also mentioned that through the hktdc.com Sourcing platform, the company received around 30 inquiries before the expo and arranged on-site meetings with several clients. The “EXHIBITION+” hybrid model has significantly boosted the company’s visibility and secure more business opportunities.The Hong Kong International Tea Fair opened to trade and public visitors on all three days for the first time. Yip Wing-chi, Founder of exhibitor, Lock Cha Tea House, welcomed this arrangement and noted that there was a significant increase in traffic, creating a lively atmosphere. The public participation has effectively boosted business. Mr Yip said this year's sales were three times higher than last year.Hybrid model connecting local and overseas opportunitiesThis year, both Food Expo PRO and the Hong Kong International Tea Fair continued to adopt the EXHIBITION+ hybrid model, enabling global food and tea buyers to engage in business discussions through both physical exhibitions and online platforms. Until 23 August, exhibitors and buyers can still utilise the "Click2Match" smart matching platform for online discussion and to explore business opportunities.Chinese Medicine Conference Gathers Experts and Scholars to Promote Industry ExchangeThe International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association in partnership with the HKTDC and ten scientific research institutions, has successfully concluded. The conference unveiled the latest professional information on traditional Chinese medicine and shared innovative achievements and development trends in the globalisation of Chinese medicine. Held concurrently with the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO, and the Hong Kong International Tea Fair, the event covered diverse fields such as food, beauty, health, home products, and Chinese medicine, successfully creating a synergistic effect, providing a broad platform for industry exchange.Photo download: http://bit.ly/4mrgT4SThe Food Expo, Home Delights Expo, and Beauty & Wellness Expo, three public exhibitions organised by the Hong Kong Trade Development Council, along with the Food Expo PRO and the Hong Kong International Tea Fair, have successfully concluded, attracting over 500,000 visits to attend and shopThe Food Expo PRO featured multiple pavilions showcasing unique culinary delights from different countries and regions, with exhibitors displaying halal food and beverage label gaining increasing attentionThe Federation of Hong Kong Industries and the Incorporated Trustees of the Islamic Community Fund of Hong Kong launched the “Hong Kong Q-Mark Halal Scheme” at the Food Expo PRO, announcing their joint efforts to promote halal certification and its development, fostering the sustainable development of halal products and culture in Hong KongAt the Food Expo PRO, the HKTDC signed a Memorandum of Understanding with The Bank of Saga Ltd., to promote businesses in Saga, Fukuoka, and Nagasaki to further their development in Hong Kong and beyond, revitalising both the local economy and prosperity of the regionThe Hong Kong International Tea Fair opened to the public for the first time over its three-day exhibition period, drawing many visitors to explore a variety of tea beveragesThe five major theme days ran throughout the exhibition period, with the opening day (14 August) featuring "Shall We Tea'”, focusing on demonstrations of Northern and Southern dim sum and creative dim sum making, tea therapy workshops and other exciting activitiesOn 15 August, “Flavours of Intangible Cultural Heritage” featured hands-on experiences in making traditional Hakka “hand-pulled” noodles, as well as introductions to intangible cultural heritage steamer and bamboo craftmanship culture, along with steamer craft demonstrationsOn 17 August, “Body, Mind & Soul” responds to the business opportunities brought by the silver economy, with exhibitors launching a variety of products and services tailored for seniorsThe Beauty & Wellness Expo has introduced a new Polish pavilion this year, showcasing high-quality products such as caviar essence cream, pure natural essential oils, hair growth serums, and other products. The newly-established "Scentsation" zone focuses on perfumes and aromatherapy, featuring over 20 participating brandsThe Home Delights Expo's "Avenue of Delights" brand zone included more than 35 exhibitors, showcasing various lifestyle brandsThroughout the exhibitions, a series of highly popular and exciting events were held, including "Star Chef Cooking Demonstrations”, "Smart Bidding", and lucky drawsThe International Conference of the Modernization of Chinese Medicine and Health Products presented the latest professional information on Chinese medicine. The conference, themed "The Latest Research Progress in the Prevention and Treatment of Tumours, Inflammation and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine", featured 21 prominent speakers, including experts from Hong Kong, mainland China, and overseas, sharing innovative achievements and development trends in the globalization of Chinese medicineTo learn more about the opinions of exhibitors and buyers, please visit:HKTDC Food Expo PROfoodexpopro.hktdc.comHong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM)icmcm.hktdc.com Media EnquiriesOgilvy Public Relations:Rex CheukTel:(852) 5618 9908email: rex.cheuk@ogilvy.comLeanne PokTel:(852) 9379 9694 email: leanne.pok@ogilvy.comDaisy LeungTel:(852) 9275 7704email: daisy.leung@ogilvy.comHKTDC’s Communications and Public Affairs Department:Stanley SoTel:(852) 2584 4049email: stanley.hp.so@hktdc.orgSerena CheungTel:(852) 2584 4272email: serena.hm.cheung@hktdc.orgClayton LauwTel:(852) 2584 4472email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

- Some 260 brands from 24 countries and regions set to participate, a new high for the event, with the UK debuting as Partner Country to present works by leading British designers- Internationally acclaimed couturier Guo Pei will stage her first solo couture show in Hong Kong, unveiling 30 meticulously crafted pieces under the theme “Gilternity: An Everlasting Radiance”- Aligning with market trends, the fair will introduce a new Accessories Zone and will once again feature the Circular Fashion Zone to promote the development of sustainable fashion- The Fashion Hong Kong Runway Show will celebrate the creative journey of local brands; around 30 fashion shows will be staged during the fair – the highest number in the event’s historyHONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Government of the Hong Kong Special Administrative Region (HKSAR), CENTRESTAGE – the annual gala event for the Asian fashion industry – takes place from 3 to 6 September 2025 at the Hong Kong Convention and Exhibition Centre (HKCEC). Unveiling a grand celebration of style for its 10th anniversary edition, this year’s CENTRESTAGE sees a record participation of some 260 brands from 24 countries and regions. The programme features more than 40 events, including around 30 fashion shows and parades – another record for the event. The four-day showcase is open to industry professionals and the public free of charge, welcoming visitors from Hong Kong, Mainland China and overseas to experience the charm and creativity of Asia’s fashion capital.Sophia Chong, Deputy Executive Director of the HKTDC, said: “Over the past decade, CENTRESTAGE has become the perfect meeting point for fashion brands and designers from across the globe, and Asia in particular, to showcase their latest creations. As the event celebrates its 10th anniversary, we are truly privileged to welcome internationally acclaimed couturier Guo Pei to present a collection at CENTRESTAGE ELITES, marking her first solo couture show in Hong Kong. As the flagship fashion event for Asia, CENTRESTAGE not only celebrates virtuosity in design and craftsmanship, but also propels both local and international brands into the broader Asian market, supporting the vigorous development of the local fashion industry and reinforcing Hong Kong’s status as a global fashion hub and world-class East-meets-West centre for cultural exchange.”This year’s CENTRESTAGE welcomes fashion brands from across the globe, including pavilions from the United Kingdom, Czech Republic, Japan and Thailand. The UK is participating for the first time as the "Partner Country" of CENTRESTAGE, showcasing unique creations from various British designers. Globally acclaimed fashion maestro Jimmy Choo will not only attend CENTRESTAGE in person but also spotlight his visionary initiative – the Jimmy Choo Academy – showcasing works by emerging designers nurtured by the Academy. The Czechia pavilion will present personalised fashion labels that incorporate art-glass design; the Japan pavilion will spotlight emerging designers and brands, showcasing the creative force of Japan’s new generation; and the Thailand pavilion returns on an unprecedented scale, leading more than 40 brands to the show and expressing the rich diversity of Southeast Asian style. Brands from South Korea, Singapore and other countries will also exhibit their collections at the fair.CENTRESTAGE ELITES sees Guo Pei’s first solo couture show in Hong KongThe prestigious opening event, CENTRESTAGE ELITES, takes place on 1 September at M+ in the West Kowloon Cultural District, with internationally acclaimed couturier Guo Pei presenting her first solo couture show in Hong Kong. Guo Pei was the first Chinese designer invited to join the Fédération de la Haute Couture et de la Mode (FHCM) while also consecutively presenting 10 showcase collections in Paris. She previously participated in HKTDC Hong Kong Fashion Week for Fall/Winter in 2010, closing the Hong Kong Fashion Extravaganza with a spectacular finale.For CENTRESTAGE ELITES, Guo will present 30 one-of-a-kind couture creations under the theme "Gilternity: An Everlasting Radiance", drawing inspiration from the dazzling, fleeting moment of flowing molten gold. Fusing traditional craftsmanship with modern art, the collection epitomises her unparalleled artistry and technical mastery. In a gesture that honours both tradition and innovation, Guo has invited students from Hong Kong Polytechnic University (PolyU) to collaborate on the opening piece for the show.This grand occasion will be livestreamed on the CENTRESTAGE website and Instagram, the HKTDC’s YouTube channel, Facebook and official pages, and across multiple platforms including ViuTV Facebook and Yahoo HK. On the second day of the event (4 September), Guo Pei will appear in person for a master sharing session, offering rare in-person insights into her creative journey and design philosophy.Fashion Hong Kong Runway Show celebrates designers’ creative journeyOn the evening of 3 September, the Fashion Hong Kong Runway Show will take the stage under the theme "A Decade in Design: What is Seen' What is Felt'", exploring Hong Kong designers’ creative journeys. Four Hong Kong designer brands – ANGUS TSUI, ARTY:ACTIVE, IP AXIS INDUSTRIALSTUDIO and selfFab. – will showcase their innovative collections, merging visual impact and emotional narrative to spotlight the unique creativity of Hong Kong fashion design.Six thematic zones showcase sustainability and diversityCENTRESTAGE will be staged across six distinctive thematic zones, each offering its own unique appeal. The new Accessories Zone will present an array of fashion jewellery, handbags, footwear and other refined fashion accents, where style and function are seamlessly intertwined. The Athleisure Zone will champion activewear that unites aesthetics with practicality, reflecting the growing prominence of sports-inspired looks. The Craftsmanship Zone will showcase exquisite techniques and artisanal mastery that pay homage to heritage skills, while the Contemporary Zone will unveil forward‑thinking, avant‑garde creations from cutting‑edge designers. The Urban Zone will spotlight youth‑driven trends, including labels such as Petrolhead, helmed by artist Louis Cheung, which fuses motorcycle culture with a streetwear edge. Completing the lineup, the Circular Fashion Zone will advocate the possibilities presented by sustainable style, headlined by the 15th Redress Design Award Final at which the winning eco‑conscious collections will be showcased, promoting the industry’s focus on environmentally friendly design.The four-day fair will present a rich variety of happenings, including student showcases from PolyU’s School of Fashion and Textiles and the Hong Kong Design Institute, as well as an interdisciplinary exhibition from the Fashion Farm Foundation that combines music, art, product design and intangible cultural heritage, featuring traditional crafts such as gold-thread embroidery in bridal gowns and the making of Canton silk. A record-breaking total of 28 fashion shows will be held throughout CENTRESTAGE, featuring brands such as 112 mountainyam, CAMMIE CHAN CHEONGSAM, DorisKath, and KOWLOON CITY BOY that showcase the vibrant energy of the fashion industry.LOCAL POWER 2025, a cross-cultural project curated by Asian New Generation Creativity Design Association, will officially launch during CENTRESTAGE. This initiative will bring together designers from Hong Kong and Korea, presenting a thoughtfully curated exhibition and runway show that will help to foster cultural and creative exchanges between the two places. “THREAD OF CREATIVITY – Fashion Design Competition 2025" and Knitwear Innovation and Design Society Limited (KIDS) featuring the Young Knitwear Designers' Contest 2025 will also be held during the fair period.The HKTDC will continue to invite buyers from around the world to source at CENTRESTAGE, including major multi-brand stores such as WDLT 117 Apparel Inc. from Canada, Zalora from Indonesia, Sugar Srl from Italy and Hankyu Hanshin Department Stores from Japan.Spotlighting new talent at the YDCThe grand finale of CENTRESTAGE 2025 on Saturday, 6 September will be the Hong Kong Young Fashion Designers’ Contest (YDC), dedicated to discovering and nurturing new local talent. This year's competition will continue to promote a spirit of innovation and experimentation, allowing participants to fully showcase their creativity while injecting fresh talent into the industry. Charles Jeffrey, the designer behind the London label Charles Jeffrey LOVERBOY, has been invited as guest judge, joining a panel of other industry professionals to select winners from the 10 finalists vying for four major awards: Champion, Excellence Award, Best Art Direction and My Favourite Collection. Members of the public are invited to participate by casting votes online (https://bit.ly/YDC2025_IG_Vote_Now) for their favourite collection. Designer brands JESSE LEE and gnastiy.com, both former participants in the YDC, will showcase their new season special collections alongside guest performers at this year's YDC finale.CENTRESTAGE will be staged in parallel with the HKTDC Hong Kong Watch & Clock Fair and Salon de TIME, with visitors able to view the latest products from some 400 watch and fashion brands at the same venue. The fairs will also feature the CENTRESTAGE x Watch & Clock Lucky Draw. The brand-new CENTRESTAGE Instagram account (@centrestage_hktdc) is now officially live and will be updated with the latest event information and fashion trends. Everyone is welcome to follow and stay closely connected with all the latest happenings at CENTRESTAGE.Photo download: https://bit.ly/47uYUFOSharing highlights of this year’s CENTRESTAGE at today’s press conference are Sophia Chong, Deputy Executive Director of the HKTDC (second right); Katherine Fang, Chairman of the HKTDC Garment Advisory Committee (second left); Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (first right); and local fashion designer Angus Tsui (first left).The 2025 CENTRESTAGE exhibition will feature some 260 brands from 24 countries and regions – the largest brand lineup in the event’s history.The grand opening event, CENTRESTAGE ELITES, will be held on 1 September at M+ in the West Kowloon Cultural District. Internationally acclaimed couturier Guo Pei will present her first-ever couture show in Hong Kong. Her "Gilternity: An Everlasting Radiance" collection was previewed at today’s press conference.Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (left), and artist Marf Yau (right) wear creations from Patrick McDowell, a brand featuring at the UK Pavillion, at the CENTRESTAGE press conference.Local designer Angus Tsui (left) and artist/emcee Thor Lok (right) showcase a fashion piece designed by Angus Tsui.Websites- CENTRESTAGE: https://www.hktdc.com/event/centrestage/en- CENTRESTAGE ELITES: https://www.hktdc.com/event/centrestage/en/centrestage-elites- CENTRESTAGE Instagram: https://www.instagram.com/centrestage_hktdc/?hl=en- Fashion Hong Kong: https://www.fashionhongkong.com.hk/en- Hong Kong Young Fashion Designers' Contest (YDC): www.fashionally.com/enMedia enquiriesBest Crew Public Relations & MarketingDiana Tang Tel: (852) 9199 6723 Email: diana.tang@bestcrewpr.comReni Kwok Tel: (852) 6291 4283 Email: reni.kwok@bestcrewpr.comHKTDC Communication and Public Affairs Department:Sharon Ha Tel: (852) 2584 4575 Email: sharon.mt.ha@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Cultural and Creative Industries Development Agency (CCIDA)The Cultural and Creative Industries Development Agency (CCIDA) established in June 2024, formerly known as Create Hong Kong (CreateHK), is a dedicated office set up by the Government of the Hong Kong Special Administrative Region (HKSAR Government) under the Culture, Sports and Tourism Bureau to provide one-stop services and support to the cultural and creative industries with a mission to foster a conducive environment in Hong Kong to facilitate the development of arts, culture and creative sectors as industries. Its strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and cross-genre collaboration, promoting the development of arts, culture and creative sectors as industries under the industry-oriented principle, and promoting Hong Kong as Asia’s creative capital and fostering a creative atmosphere in the community to implement Hong Kong’s positioning as the East-meets-West centre for international cultural exchange under the National 14th Five-Year Plan.CCIDA’s website: www.ccidahk.gov.hkDisclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 2025 年8月17 日，全球首个以人形机器人为核心参赛主体的大型综合性赛事——世界人形机器人运动会，在北京国家速滑馆"冰丝带"圆满落幕。本届运动会由北京市人民政府、中央广播电视总台、世界机器人合作组织、亚太机器人世界杯国际理事会等单位联合主办，集聚全球 280 支战队、500 余台机器人同台竞技，展现了具身智能机器人从技术突破走向场景应用的完整产业链条。在本次大会中，首程控股（0697.HK）作为深度产业推动者，多家被投企业集体亮相，参与多个重点项目并获得优异成绩，共计斩获37枚奖牌，其中包括12金14银11铜（包括各战队使用被投企业本体机器人参赛获奖情况）。与此同时，首程控股还在"冰丝带"外场打造了面向公众开放的"首程机器人科技体验店"，成为大会期间最受关注的互动展区之一。一、多家被投企业集结亮相本次赛事首程控股本次参展的多家企业涵盖了人形机器人本体、底层技术平台、零部件能力与具身智能生态的多个核心环节：宇树科技：在 2025 世界人形机器人运动会圆满落幕之际，宇树科技以出色的表现获得了四金，再次证明了其在全球人形机器人领域的技术领先地位。宇树科技的机器人在多个项目中表现卓越，分别夺得1500米、400米、100米障碍赛和 4×100米接力赛的金牌，展现了其在速度、灵活性和稳定性方面的强大实力。此外，在本届赛事中，宇树科技的机器人最高速度达到了 4.78m/s，这一成绩距离其内部测试的 5+m/s 还有一定差距，未来在速度和灵活性方面仍有巨大的提升空间。基于宇树科技 G1 硬件平台开发的独立参赛队伍也取得了不俗成绩，分别获得了1金1银1铜，进一步验证了宇树科技平台的广泛适应性与强大性能。北京人形机器人创新中心：在2025世界人形机器人运动会上，北京人形机器人创新中心展现了卓越的技术实力和广泛的场景适应能力，累计斩获2金6银2铜，成为本届赛事最具代表性的"全自主执行"技术方之一。在竞技赛部分，其打造的"天工 Ultra"机器人是 1500 米比赛中唯一全程自主奔跑、无遥控介入的选手，最终获得银牌；在 100 米项目中夺得金牌，在 400 米项目中拿下银牌与铜牌各一枚，并在 4×100 米接力赛中获得银牌，全面展示了其在复杂运动控制、节奏协调与导航算法方面的领先优势。在场景赛中，创新中心自主研发的天轶 2.0 机器人，凭借慧思开物"具身大脑+具身小脑"的智能协同体系，在"物料整理"项目中包揽金银牌，在"物料搬运"项目中斩获银牌与铜牌，并在"酒店迎宾服务技能竞赛"中收获银牌。这些项目均要求高度精细化操作与复杂场景适应能力，充分体现了其在"自主感知-智能决策-精准执行"完整闭环中的技术突破。作为本届赛事中"全自主"能力最突出的参赛单位，北京人形机器人创新中心不仅实现了从实验室走向复杂实战场景的关键跨越，也为具身智能的落地提供了极具参考价值的技术路径。松延动力：在本次运动会自由体操项目中，由松延动力自主研发的人形机器人"小顽童"以出色的平衡性、动态控制与节奏感，夺得冠军，展现出融合 AI 与动态模仿控制的高水平舞台表现力；博远智行 1 队采用松延动力机器人参赛，也在同一项目中荣获季军。在跳远项目中，松延动力的机器人再次发挥出色，赢得了冠军，展示了其在运动精度与协调性方面的强大能力。在单机舞蹈项目中，松延动力联合北京舞蹈学院组建代表队参赛，凭借对细节动作的精准复现和对舞台艺术的深度理解，最终斩获亚军，成为本届赛事"科技×艺术"融合的典范之一。松延动力此次在体操、跳远和舞蹈三个项目中斩获二金一银一铜，不仅证明了其机器人平台在高动态控制与 AI 动作生成领域的前沿实力，也进一步拓宽了人形机器人在文教娱乐、公共服务等方向的实际应用边界。银河通用：在首届世界人形机器人运动会中，银河通用 Galbot 队凭借全自主操作勇夺分拣技能竞技冠军。同时，来自中国矿业大学的北京北矿梦之队和北京建筑大学队等多支高校队伍也选择银河通用机器人参赛，均成功闯入复赛，其中矿大与北建大更是闯入决赛，最终分获亚军与第四名。至此，冠亚军由银河通用及采用银河通用机器人的队伍共同包揽，充分展现了银河通用技术的行业引领性与产品的通用性。星海图：在本次运动会中，星海图深度参与赛事生态构建，作为场景赛独家整机提供商，提前三周入驻实训场，为来自全国的 20 余支顶尖团队（包括北京林业大学、清华大学、北京航空航天大学等）提供总计 8 台人形机器人 R1 Pro、通用双臂移动操作平台 R1 Lite 及配套 VR 设备，并搭建开放软硬件平台，支撑参赛团队将创新算法从仿真环境部署至真实场景。场景赛覆盖的场景包括，酒店服务（床铺整理、迎宾行李搬运）、仓储中心（混合物料分拣）、医院场景（药品识别与补货）及工业场景（异物分拣与物料搬运）。走进冰丝带，就能看到星海图机器人和参赛选手们忙碌的身影。本次比赛中，来自北京航空航天大学的代表队采用星海图本体参与拆药分装场景赛，并成功获得季军，充分验证了星海图为开发者提供的具身智能开发平台的能力。加速进化：作为足球项目的核心技术支持方，加速进化为 3V3、5V5 等全部足球项目提供了竞技型人形机器人，承担了赛事中全部参赛队伍的机器人硬件支持与赛中技术保障。提供的机器人以高动态控制能力、抗干扰能力和场景适应性著称，展现了良好的对抗与战术执行能力。虽不作为直接参赛队伍名义参赛，但加速进化提供的技术平台承载了赛事中全部足球类奖牌的实现，是足球项目"幕后冠军"。二、科技体验走进生活，打造机器人产业"样板间"大会期间，首程控股在场馆外开设的"首程机器人科技体验店"也成为市民与游客热烈打卡的科技热点。店内集中展出200余款智能产品，涵盖智慧家居、儿童教育、AI娱乐、智能穿戴、户外运动等多个生活化场景。体验区共分为生态企业展示区、儿童互动区、医疗辅助区、AI音乐互动区等多个版块，成为让机器人"看得见、摸得着、用得上"的现实样本。首程控股执委、联席总裁叶芊在接受采访时表示："我们希望通过这次展示，让大家感受到机器人离生活越来越近。场馆内比的是专业能力，我们的体验店则通过贴近真实场景的互动设计，拉近机器人与大众的距离。"体验店内各展区的亮点纷呈：生态展示区以松延动力为代表，展示具备表情识别、人脸互动能力的拟人机器人，体现大模型与形态融合的前沿趋势；儿童体验区配置了汤姆猫、国际象棋机器人、AI 陪伴机器人和扫地机器人等设备，是全店人气最高区域；外骨骼与康复区设置跑步机、自行车等模拟设备，观众可实地体验机器人助力运动；智能穿戴区引入光粒品牌游泳眼镜，具备实时导航和运动数据采集能力；人机互动区展示了机器人自主演奏乐器及 AI 打击乐器、智能电吉他产品，深受观众欢迎；同时展出的还有 AI 中医问诊设备、具身底盘平台、机械臂抓取系统等，体现了机器人从"有脑、有脚、有手"的系统能力整合。三、首家正式体验店即将开业，全国推广启动在即本次"首程机器人科技体验店"为快闪形式试运营，但已获得极大市场关注。正式体验店预计将于"十一"期间在北京石景山-融石广场开业，后续还将布局至全国多个城市与重点场景（机场、高校、商圈等），形成连锁化、场景化的销售与体验网络。叶芊表示："我们将其定位为面向 C 端用户与城市生活空间的机器人应用窗口，也希望通过这类门店，持续验证市场需求、推动产品优化，帮助更多机器人企业走向商业化落地。"四、每一块奖牌，都是机器人走向未来的一小步人形机器人产业正在迎来从实验室走向真实场景的拐点。正如首程控股董事会办公室总经理康雨所指出："这场运动会，不仅比拼技术的高度，更关乎产业的温度--是一次让机器人真正走向应用、走进生活的生动演练。"未来，首程控股将持续依托"股权投资+资产运营"双轮驱动战略，携手被投企业与行业伙伴，推动机器人从看得见、摸得着的技术突破，走向用得上、可推广的现实应用，在教育、制造、城市运营、医疗康养等核心领域释放"下一代生产力"的真正价值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - On August 17, 2025, the inaugural World Humanoid Robot Games—an international event centered on humanoid robots—concluded successfully at the National Speed Skating Oval in Beijing, also known as the “Ice Ribbon.”Co-hosted by the Beijing Municipal Government, China Media Group, the World Robot Cooperation Organization, and the Asia-Pacific RoboCup Council, the Games gathered 280 teams and over 500 robots from around the globe to compete across 26 disciplines, showcasing the full industrial chain from technological breakthroughs to real-world applications in embodied intelligence.As a key industrial accelerator, Shoucheng Holdings (0697.HK) saw several of its portfolio companies participate in major events, collectively winning 37 medals (12 gold, 14 silver, and 11 bronze), including awards where teams utilized robots built by Shoucheng’s portfolio firms. Simultaneously, Shoucheng launched the "Shoucheng Robot Tech Experience Store" adjacent to the venue, which became one of the most visited tech exhibits of the event.Highlights from Portfolio Companies:Unitree Robotics captured 4 gold medals and achieved a top speed of 4.78 m/s; G1-based teams earned an additional 1 gold, 1 silver, and 1 bronze;Beijing Humanoid Robot Innovation Center won 2 gold, 6 silver, and 2 bronze, representing the most advanced “fully autonomous execution” capabilities;Noetix Robotics earned 2 gold, 1 silver, and 1 bronze in gymnastics, long jump, and dance events, becoming a standout in “Tech × Art” integration;Galbot (by Galbot Technologies) secured the autonomous sorting championship and supported university teams that swept the podium;Galaxea-AI served as exclusive hardware provider in scene-based competitions and enabled a third-place finish by Beihang University;Booster Robotics powered all 3V3 and 5V5 football events, providing robot hardware and technical support, and was deemed the “backstage champion.”Robot Tech Experience Store: Bringing Innovation to the EverydayDuring the event, Shoucheng launched a pop-up “Robot Tech Experience Store,” featuring over 200 smart products across home, education, entertainment, healthcare, and wearables. The official store will open during China’s National Day Golden Week in October 2025 at Fusion Stone Plaza, Beijing, with nationwide expansion plans into airports, campuses, and commercial hubs.As Shoucheng’s Executive Director and Co-President Ye Qian stated: “Through interactive and relatable scenarios, we want the public to feel that robots are no longer distant technologies—they’re becoming part of daily life.”From Lab to Market: Accelerating the New Productive ForceWith a dual strategy of equity investment and asset operations, Shoucheng Holdings will continue to drive commercialization of humanoid and embodied robots in education, manufacturing, healthcare, and smart city operations, unlocking the full potential of the next-generation productivity paradigm.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

重点成果- 期内，集团共有2个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因子VIIa N01）。- 2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。- 截至2025年6月30日，集团共有37个肿瘤领域、7个肝病╱代谢领域、13个呼吸系统领域、和6个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中，2个肿瘤领域、1个外科╱镇痛领域产品处在上市申请阶段；11个肿瘤领域、1个肝病╱代谢领域、3个呼吸系统领域、1个外科╱镇痛领域的创新候选药物处于临床III期；另有13个肿瘤领域、6个肝病╱代谢领域、12个呼吸系统领域、6个外科╱镇痛领域的生物类似药或仿制药候选药物处于临床申请及以上开发阶段。- 福可维（盐酸安罗替尼胶囊）是一种新型小分子多靶点酪氨酸激酶抑制剂，目前已获批9个适应症，另有3个适应症处于上市申请阶段。此外，安罗替尼还有多项新适应症处于III期临床研究阶段，包括一线非鳞状非小细胞肺癌、一线胰腺癌等，预计将在未来两年逐步递交上市申请。- 2023-2024年，集团共有5款肿瘤领域的国家1类创新药获批上市，分别为：亿立舒（艾贝格司亭α注射液）、安得卫（贝莫苏拜单抗注射液）、安柏尼（富马酸安奈克替尼胶囊）、安洛晴（枸橼酸依奉阿克胶囊）和安方宁（格索雷塞片）；以及4款肿瘤领域的生物类似药获批上市，分别为：安倍斯（贝伐珠单抗注射液）、得利妥（利妥昔单抗注射液）、赛妥（注射用曲妥珠单抗）和帕乐坦（帕妥珠单抗注射液）。该等产品在2025年上半年快速放量，成为集团收入增长的重要贡献品种。- 拉尼兰诺（泛PPAR激动剂）是一种口服小分子药物，用于治疗代谢功能障碍相关脂肪性肝炎（MASH），目前正在全球开展III期临床试验，已完成全部受试者入组。2023年7月，拉尼兰诺被药品评审中心「CDE」纳入突破性治疗药物程序。拉尼兰诺是中国第一个进入临床III期的MASH口服药物，有望填补中国市场空白。- 天晴速畅（吸入用布地奈德混悬液）是中国首款获批上市的布地奈德雾化剂型仿制药，打破了国内市场长期被原研垄断的局面，为国内气道慢性炎症患者带来了兼具有效性、安全性与经济性的高端制剂产品。该产品已被纳入集采范围，集团及时采取了一系列主动管理措施，包括管道下沉、拓展市场覆盖和集采外市场的二次开发。- 泽普思╱得百安（氟比洛芬凝胶贴膏）是中国首个获批上市的国产凝胶贴膏，连续多年蝉联外用镇痛市场份额第一位。集团聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求，推动泽普思/得百安销售额持续快速增长。集团开发的第二代氟比洛芬贴剂预计将在一年内获批上市。通过剂型升级，二代产品可显著提高药物透皮吸收度，增强贴膏粘附性，从而提升患者的依从性。香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 中国领先的创新研发驱动型医药集团-中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2025年6月30日止6个月（「期内」）之未经审核财务业绩。回顾期内，集团收入同比增长10.7%至约175.7亿元（人民币，下同）。来自持续经营业务之归属于母公司持有者应占盈利财务报表所示约33.9亿元，同比增长约140.2%，基于归属于母公司持有者应占盈利计算之每股盈利约18.82分。归属于母公司持有者盈利同比显著增长主要受惠于本期间收入明显增长及股息收益和投资公允价值变动收益明显增长。归属于母公司持有者之基本溢利（非香港财务报告准则指标）约30.9亿元，同比增长约101.1%。集团流动资金保持充裕，期内有计入流动资产之现金及银行结余约111亿元、计入非流动资产之银行存款约101亿元，理财管理产品总额约92.9亿元，资金储备合共约304.9亿元。董事会建议派发中期股息每股5港仙（2024上半年：3港仙）。销售：研发创新动能强劲，多领域销售成果持续放量集团一直以来重视研发，持续加大投入以提升研发质效，研发实力显著增强，驱动销售收入持续增长，成果丰硕。期内，抗肿瘤用药之收入同比增加24.9%，达约66.9亿元，占集团收入约38.1%。外科／镇痛用药之收入同比增加20.2%，达约31.1亿元，占集团收入约17.7%。肿瘤领域，集团全面布局非小细胞肺癌领域，覆盖多种分型的全线治疗，EGFR/cMet双抗TQB2922即将启动二线非小细胞肺癌III期临床，EGFR/cMet双抗ADC TQB6411 I期临床正在入组，两款产品进度均位于中国前列；深度布局乳腺癌三大亚型， CDK2/4/6抑制剂库莫西利胶囊有望成为HR+/HER2-乳腺癌的BIC疗法，HER2双抗ADC TQB2102较DS-8201潜在安全性优效，多个适应症正在同步拓展，其中三项乳腺癌III期快速推进；系统布局消化道领域结直肠癌、胃癌、胰腺癌、肝癌等核心癌肿，LM-108(CCR8单抗)、TQB2868(PD-1/TGF-β双功能融合蛋白)研发进度全球最快，且目前临床数据展示出了极大潜力。于外科╱镇痛领域，集团持续聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求。期内，集团推动泽普思销售额持续快速增长，而开发的第二代氟比洛芬贴剂预计将在一年内获批上市。同时，2025年5月获批的普坦宁凭借长效镇痛、安全性优异等优势，有望成为该领域新的增长动力。研发：全力以赴推动创新产品开发，加大研发的资金投入于报告期内，集团共有2个创新产品获NMPA批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因数VIIa N01）。2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。一直以来，集团十分重视研发，不断提升研发水平和速度，并视其为可持续发展的基础，加大研发的资金投入。截至二零二五年六月三十日止六个月，研究与开发成本约人民币318,756万元，占本集团收入约18.1%，连同已资本化的研发总开支出在内，约95.7%已计入损益表中。展望：深化创新与国际化布局，加速构建全球医药创新竞争力当前，中国医药产业正迎来历史性发展机遇。在国家创新驱动发展战略的指引下，我国生物医药创新能力显著提升，创新药研发已从「跟跑」逐步迈向「并跑」甚至「领跑」阶段。中国创新药不仅在本土市场构建起强劲的增长势能，更在全球市场逐步崭露头角，日益获得广泛认可，已成为全球医药创新产业中不可替代的重要力量。作为行业领军企业，集团深耕肿瘤、肝病╱代谢、呼吸系统及外科╱镇痛四大核心治疗领域，专注创新，服务病患，目标成为全球领先的制药企业。集团深耕中国市场，同时将战略视野投向全球市场，以国际化加速创新发展。同时，集团大力推进全球战略合作布局，通过商务拓展（BD）、战略收购等多元合作路径，快速充实创新管线储备，强化核心技术平台。2025年7月，集团宣布全资收购礼新医药。礼新医药拥有全球领先的抗体发现和ADC技术平台，包括肿瘤微环境特异性抗体开发平台 (LM-TME™)、针对难成药靶点的抗体开发平台（LM-Abs™），新一代抗体偶联药物平台（LM-ADC™）、以及免疫细胞衔接器平台（LM-TCE™）。此次收购将进一步增强集团的创新研发能力，加速集团的创新业务增长。此外，礼新医药卓越高效的研发团队将加入集团，进一步强化集团的创新研发人才储备，为持续产出高水平创新成果提供保障，助力创新生态的长远发展。未来，本集团将继续聚焦创新，提升四大治疗领域的研发效率与质量，加快国际化步伐，力争实现业务快速发展与业绩稳步提升。有关中国生物制药有限公司（股票编号：1177）中国生物制药，连同其附属公司，是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智慧化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病/代谢、呼吸系统、外科/镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市，2013年入选MSCI全球标准指数之中国指数成分股；2018年入选恒生指数成分股；2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续七年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」，连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料，请浏览: www.sinobiopharm.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 2025 年8月17 日，全球首个以人形机器人为核心参赛主体的大型综合性赛事——世界人形机器人运动会，在北京国家速滑馆"冰丝带"圆满落幕。本届运动会由北京市人民政府、中央广播电视总台、世界机器人合作组织、亚太机器人世界杯国际理事会等单位联合主办，集聚全球 280 支战队、500 余台机器人同台竞技，展现了具身智能机器人从技术突破走向场景应用的完整产业链条。在本次大会中，首程控股（0697.HK）作为深度产业推动者，多家被投企业集体亮相，参与多个重点项目并获得优异成绩，共计斩获37枚奖牌，其中包括12金14银11铜（包括各战队使用被投企业本体机器人参赛获奖情况）。与此同时，首程控股还在"冰丝带"外场打造了面向公众开放的"首程机器人科技体验店"，成为大会期间最受关注的互动展区之一。一、多家被投企业集结亮相本次赛事首程控股本次参展的多家企业涵盖了人形机器人本体、底层技术平台、零部件能力与具身智能生态的多个核心环节：宇树科技：在 2025 世界人形机器人运动会圆满落幕之际，宇树科技以出色的表现获得了四金，再次证明了其在全球人形机器人领域的技术领先地位。宇树科技的机器人在多个项目中表现卓越，分别夺得1500米、400米、100米障碍赛和 4×100米接力赛的金牌，展现了其在速度、灵活性和稳定性方面的强大实力。此外，在本届赛事中，宇树科技的机器人最高速度达到了 4.78m/s，这一成绩距离其内部测试的 5+m/s 还有一定差距，未来在速度和灵活性方面仍有巨大的提升空间。基于宇树科技 G1 硬件平台开发的独立参赛队伍也取得了不俗成绩，分别获得了1金1银1铜，进一步验证了宇树科技平台的广泛适应性与强大性能。北京人形机器人创新中心：在2025世界人形机器人运动会上，北京人形机器人创新中心展现了卓越的技术实力和广泛的场景适应能力，累计斩获2金6银2铜，成为本届赛事最具代表性的"全自主执行"技术方之一。在竞技赛部分，其打造的"天工 Ultra"机器人是 1500 米比赛中唯一全程自主奔跑、无遥控介入的选手，最终获得银牌；在 100 米项目中夺得金牌，在 400 米项目中拿下银牌与铜牌各一枚，并在 4×100 米接力赛中获得银牌，全面展示了其在复杂运动控制、节奏协调与导航算法方面的领先优势。在场景赛中，创新中心自主研发的天轶 2.0 机器人，凭借慧思开物"具身大脑+具身小脑"的智能协同体系，在"物料整理"项目中包揽金银牌，在"物料搬运"项目中斩获银牌与铜牌，并在"酒店迎宾服务技能竞赛"中收获银牌。这些项目均要求高度精细化操作与复杂场景适应能力，充分体现了其在"自主感知-智能决策-精准执行"完整闭环中的技术突破。作为本届赛事中"全自主"能力最突出的参赛单位，北京人形机器人创新中心不仅实现了从实验室走向复杂实战场景的关键跨越，也为具身智能的落地提供了极具参考价值的技术路径。松延动力：在本次运动会自由体操项目中，由松延动力自主研发的人形机器人"小顽童"以出色的平衡性、动态控制与节奏感，夺得冠军，展现出融合 AI 与动态模仿控制的高水平舞台表现力；博远智行 1 队采用松延动力机器人参赛，也在同一项目中荣获季军。在跳远项目中，松延动力的机器人再次发挥出色，赢得了冠军，展示了其在运动精度与协调性方面的强大能力。在单机舞蹈项目中，松延动力联合北京舞蹈学院组建代表队参赛，凭借对细节动作的精准复现和对舞台艺术的深度理解，最终斩获亚军，成为本届赛事"科技×艺术"融合的典范之一。松延动力此次在体操、跳远和舞蹈三个项目中斩获二金一银一铜，不仅证明了其机器人平台在高动态控制与 AI 动作生成领域的前沿实力，也进一步拓宽了人形机器人在文教娱乐、公共服务等方向的实际应用边界。银河通用：在首届世界人形机器人运动会中，银河通用 Galbot 队凭借全自主操作勇夺分拣技能竞技冠军。同时，来自中国矿业大学的北京北矿梦之队和北京建筑大学队等多支高校队伍也选择银河通用机器人参赛，均成功闯入复赛，其中矿大与北建大更是闯入决赛，最终分获亚军与第四名。至此，冠亚军由银河通用及采用银河通用机器人的队伍共同包揽，充分展现了银河通用技术的行业引领性与产品的通用性。星海图：在本次运动会中，星海图深度参与赛事生态构建，作为场景赛独家整机提供商，提前三周入驻实训场，为来自全国的 20 余支顶尖团队（包括北京林业大学、清华大学、北京航空航天大学等）提供总计 8 台人形机器人 R1 Pro、通用双臂移动操作平台 R1 Lite 及配套 VR 设备，并搭建开放软硬件平台，支撑参赛团队将创新算法从仿真环境部署至真实场景。场景赛覆盖的场景包括，酒店服务（床铺整理、迎宾行李搬运）、仓储中心（混合物料分拣）、医院场景（药品识别与补货）及工业场景（异物分拣与物料搬运）。走进冰丝带，就能看到星海图机器人和参赛选手们忙碌的身影。本次比赛中，来自北京航空航天大学的代表队采用星海图本体参与拆药分装场景赛，并成功获得季军，充分验证了星海图为开发者提供的具身智能开发平台的能力。加速进化：作为足球项目的核心技术支持方，加速进化为 3V3、5V5 等全部足球项目提供了竞技型人形机器人，承担了赛事中全部参赛队伍的机器人硬件支持与赛中技术保障。提供的机器人以高动态控制能力、抗干扰能力和场景适应性著称，展现了良好的对抗与战术执行能力。虽不作为直接参赛队伍名义参赛，但加速进化提供的技术平台承载了赛事中全部足球类奖牌的实现，是足球项目"幕后冠军"。二、科技体验走进生活，打造机器人产业"样板间"大会期间，首程控股在场馆外开设的"首程机器人科技体验店"也成为市民与游客热烈打卡的科技热点。店内集中展出200余款智能产品，涵盖智慧家居、儿童教育、AI娱乐、智能穿戴、户外运动等多个生活化场景。体验区共分为生态企业展示区、儿童互动区、医疗辅助区、AI音乐互动区等多个版块，成为让机器人"看得见、摸得着、用得上"的现实样本。首程控股执委、联席总裁叶芊在接受采访时表示："我们希望通过这次展示，让大家感受到机器人离生活越来越近。场馆内比的是专业能力，我们的体验店则通过贴近真实场景的互动设计，拉近机器人与大众的距离。"体验店内各展区的亮点纷呈：生态展示区以松延动力为代表，展示具备表情识别、人脸互动能力的拟人机器人，体现大模型与形态融合的前沿趋势；儿童体验区配置了汤姆猫、国际象棋机器人、AI 陪伴机器人和扫地机器人等设备，是全店人气最高区域；外骨骼与康复区设置跑步机、自行车等模拟设备，观众可实地体验机器人助力运动；智能穿戴区引入光粒品牌游泳眼镜，具备实时导航和运动数据采集能力；人机互动区展示了机器人自主演奏乐器及 AI 打击乐器、智能电吉他产品，深受观众欢迎；同时展出的还有 AI 中医问诊设备、具身底盘平台、机械臂抓取系统等，体现了机器人从"有脑、有脚、有手"的系统能力整合。三、首家正式体验店即将开业，全国推广启动在即本次"首程机器人科技体验店"为快闪形式试运营，但已获得极大市场关注。正式体验店预计将于"十一"期间在北京石景山-融石广场开业，后续还将布局至全国多个城市与重点场景（机场、高校、商圈等），形成连锁化、场景化的销售与体验网络。叶芊表示："我们将其定位为面向 C 端用户与城市生活空间的机器人应用窗口，也希望通过这类门店，持续验证市场需求、推动产品优化，帮助更多机器人企业走向商业化落地。"四、每一块奖牌，都是机器人走向未来的一小步人形机器人产业正在迎来从实验室走向真实场景的拐点。正如首程控股董事会办公室总经理康雨所指出："这场运动会，不仅比拼技术的高度，更关乎产业的温度--是一次让机器人真正走向应用、走进生活的生动演练。"未来，首程控股将持续依托"股权投资+资产运营"双轮驱动战略，携手被投企业与行业伙伴，推动机器人从看得见、摸得着的技术突破，走向用得上、可推广的现实应用，在教育、制造、城市运营、医疗康养等核心领域释放"下一代生产力"的真正价值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，旗下创新药艾曲莫德（VELSIPITY(R)，etrasimod）被纳入《2025 ACG 临床指南：成人溃疡性结肠炎》（下称"新版指南"），并获得强烈推荐用于中重度活动性溃疡性溃疡性结肠炎（UC）患者的诱导缓解及维持缓解治疗（中等质量证据）。新版指南同时建议，对于已通过鞘氨醇-1-磷酸（S1P）受体调节剂实现诱导缓解的患者，继续使用艾曲莫德以维持缓解（强烈推荐，中等质量证据）。这一重要进展不仅体现了国际权威医学指南对艾曲莫德临床价值的高度认可，也进一步彰显了其在满足UC患者未被满足的治疗需求方面的潜力，为全球UC患者提供新的治疗选择。此次新版指南由美国胃肠病学会（American College of Gastroenterology，ACG）制定，基于近五年最新循证医学证据，系统总结了UC治疗及并发症预防的新方法与新进展，为临床医生提供规范、科学的管理参考，以更好地应对不同程度的UC患者治疗需求。新版指南指出，艾曲莫德作为新一代高选择性S1P受体调节剂，通过将活化的淋巴细胞滞留于淋巴结中，减少其在肠道中的浸润，从而降低局部炎症反应，并伴随外周循环淋巴细胞计数下降。艾曲莫德ELEVATE UC III 期注册研究（ELEVATE UC 52和ELEVATE UC 12）这两项随机、双盲、安慰剂对照研究均达到了所有主要和关键次要终点，分别在第12周和第52周显著改善临床缓解率，并实现持久的内镜下深度黏膜愈合。值得注意的是，研究中100%的临床缓解均为无激素缓解，安全性良好，与既往研究结果一致。指南也特意强调了与其他现有治疗不同的是，艾曲莫德 ELEVATE UC III 期注册研究中纳入了溃疡性直肠炎，且证实了在此类人群中显著提升了临床缓解率（治疗12周时，43.2% vs 13.6%, p＜0.001）。此前，艾曲莫德还被纳入2024年美国胃肠病学协会（AGA）临床实践指南, 推荐作为溃疡性结肠炎的一线治疗。艾曲莫德亚太临床试验牵头研究者、世界胃肠病学会司库、亚太消化病学会副主席、中华医学会第十届消化病学分会副主任委员、中国人民解放军第四军医大学附属西京医院吴开春教授表示："新版指南进一步明确，'实现内镜黏膜愈合以达成持续无激素缓解和避免住院手术'是中重度溃疡性结肠炎治疗的核心目标，这不仅关系到疾病的长期安全管理，也与改善患者生活质量息息相关。此次指南中，艾曲莫德被强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗，标志着其临床价值获得了国际权威学术机构的高度认可，也为临床实践提供了全新的治疗选择。"云顶新耀首席执行官罗永庆表示："艾曲莫德此次获新版指南强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗，充分体现了其卓越的临床疗效和良好安全性，进一步确立了其作为一线治疗新选择的重要地位。新版指南明确将实现内镜黏膜愈合作为治疗中重度活动性溃疡性结肠炎的核心目标，印证了黏膜愈合为国内外指南一致认定的重要终点，可显著降低疾病复发、住院、结直肠切除及结直肠癌风险。值得一提的是，指南特别强调了艾曲莫德在溃疡性直肠炎患者中同样可显著提升临床缓解率。在亚洲，溃疡性结肠炎患者人数持续上升，以中国为例，2024年中国的溃疡性结肠炎患者数量约为80万人，预计到2030年将达100万人，现有临床治疗选择有限，迫切需要兼顾疗效、安全性与便利性的创新方案。我们将加速艾曲莫德的商业化进程，助力更多患者长期维持安全有效的疾病缓解，并提升生活质量。"作为云顶新耀在自身免疫疾病领域布局的核心创新产品，艾曲莫德（维适平(R)）的新药上市申请已于2024年12月获中国国家药品监督管理局正式受理，预计今年年底或明年年初获批。艾曲莫德已在新加坡、中国澳门和中国香港获批，其新药上市许可申请也已在韩国和中国台湾地区获正式受理。艾曲莫德已被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录（2024年），在大湾区先行使用，成为云顶新耀第三款商业化新药。云顶新耀已于2025年3月启动艾曲莫德在嘉善工厂的本地化生产建设项目，支持其在大中华区及其他亚洲市场的供应及商业化落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.